{
  "title": "Review and Evaluation of Clinical Data",
  "outline": [
    {
      "level": "H2",
      "text": "Review and Evaluation of Clinical Data",
      "page": 1
    },
    {
      "level": "H1",
      "text": "NDA (Serial Number)",
      "page": 1
    },
    {
      "level": "H2",
      "text": "20823 (SE1-016)",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Sponsor:",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Novartis",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Drug:",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Exelon® (rivastigmine tartrate)",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Proposed Indication:",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Dementia Associated With Parkinson's Disease",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Material Submitted:",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Supplemental New Drug Application",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Correspondence Date:",
      "page": 1
    },
    {
      "level": "H2",
      "text": "8/31/05",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Date Received / Agency:",
      "page": 1
    },
    {
      "level": "H2",
      "text": "9/1/05",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Date Review Completed",
      "page": 1
    },
    {
      "level": "H2",
      "text": "4/18/06",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Reviewer:",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Ranjit B. Mani, M.D.",
      "page": 1
    },
    {
      "level": "H1",
      "text": "TABLE OF CONTENTS",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Executive Summary..............................................................................................3",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Efficacy Study .....................................................................................................10",
      "page": 1
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 2
    },
    {
      "level": "H2",
      "text": "10.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "This Application...................................................................................................67",
      "page": 2
    },
    {
      "level": "H2",
      "text": "11.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "Disease, And Appropriateness Of ADAS-Cog And ADCS-ADL In Evaluating",
      "page": 2
    },
    {
      "level": "H2",
      "text": "Treatment Effects In Dementia Associated With Parkinson’s Disease ...............69",
      "page": 2
    },
    {
      "level": "H2",
      "text": "12.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "This certification has been provided on FDA Form 3454. ...................................77",
      "page": 2
    },
    {
      "level": "H2",
      "text": "This certification has been provided on FDA Form 3455. ...................................77",
      "page": 2
    },
    {
      "level": "H2",
      "text": "13.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "14.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "15.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "16.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "17.",
      "page": 2
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 3
    },
    {
      "level": "H1",
      "text": "Executive Summary",
      "page": 3
    },
    {
      "level": "H1",
      "text": "Recommendation",
      "page": 3
    },
    {
      "level": "H2",
      "text": "Deferred, pending discussion of this application at a scheduled meeting of the",
      "page": 3
    },
    {
      "level": "H2",
      "text": "Peripheral and Central Nervous Systems Drugs Advisory Committee",
      "page": 3
    },
    {
      "level": "H1",
      "text": "Proposed Indication",
      "page": 3
    },
    {
      "level": "H2",
      "text": "“Treatment of mild to moderate dementia associated with Parkinson’s Disease”",
      "page": 3
    },
    {
      "level": "H1",
      "text": "Summary Of Clinical Findings",
      "page": 3
    },
    {
      "level": "H2",
      "text": "Exelon® is currently approved for marketing in this country, as both capsule and",
      "page": 3
    },
    {
      "level": "H2",
      "text": "oral solution formulations, for the treatment of mild to moderate dementia of the",
      "page": 3
    },
    {
      "level": "H2",
      "text": "Alzheimer’s type.",
      "page": 3
    },
    {
      "level": "H2",
      "text": "The sponsor has provided evidence from two completed clinical studies in",
      "page": 3
    },
    {
      "level": "H2",
      "text": "support of the efficacy and safety of Exelon® for the proposed new indication.",
      "page": 3
    },
    {
      "level": "H2",
      "text": "These are:",
      "page": 3
    },
    {
      "level": "H2",
      "text": "In addition, the sponsor has performed a non-interventional study (Study 2314) of",
      "page": 3
    },
    {
      "level": "H2",
      "text": "the validity of a number of assessment scales in the Parkinson’s Disease",
      "page": 3
    },
    {
      "level": "H2",
      "text": "Dementia (and vascular dementia); partial results for this study have been",
      "page": 3
    },
    {
      "level": "H2",
      "text": "submitted in this application.",
      "page": 3
    },
    {
      "level": "H2",
      "text": "The data for these studies as they pertain to the efficacy and safety of Exelon® in",
      "page": 3
    },
    {
      "level": "H2",
      "text": "this population are summarized below, as are the results of the non-",
      "page": 3
    },
    {
      "level": "H2",
      "text": "interventional validation study listed above.",
      "page": 3
    },
    {
      "level": "H2",
      "text": "Efficacy",
      "page": 3
    },
    {
      "level": "H2",
      "text": "The results of a single randomized, double-blind, placebo-controlled study (also",
      "page": 3
    },
    {
      "level": "H2",
      "text": "referred to as the EXPRESS Study) of the efficacy of rivastigmine in the",
      "page": 3
    },
    {
      "level": "H2",
      "text": "proposed entity of dementia associated with Parkinson’s Disease (also referred",
      "page": 3
    },
    {
      "level": "H2",
      "text": "to interchangeably as Parkinson’s Disease Dementia) have been submitted in",
      "page": 3
    },
    {
      "level": "H2",
      "text": "this application.  The main features of this study were as follows",
      "page": 3
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 4
    },
    {
      "level": "H2",
      "text": "Key results for this study were as follows.",
      "page": 4
    },
    {
      "level": "H2",
      "text": "541 patients were randomized, of whom 442 patients completed the study. Their",
      "page": 4
    },
    {
      "level": "H2",
      "text": "distribution by treatment group was as follows:",
      "page": 4
    },
    {
      "level": "H2",
      "text": "Treatment Group",
      "page": 4
    },
    {
      "level": "H2",
      "text": "Number randomized",
      "page": 4
    },
    {
      "level": "H2",
      "text": "Number completed",
      "page": 4
    },
    {
      "level": "H2",
      "text": "The main efficacy results of this study were as follows",
      "page": 4
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 5
    },
    {
      "level": "H2",
      "text": "Safety",
      "page": 5
    },
    {
      "level": "H2",
      "text": "Study 2311",
      "page": 5
    },
    {
      "level": "H2",
      "text": "This study has already been summarized above. Salient safety findings for this",
      "page": 5
    },
    {
      "level": "H2",
      "text": "study were as follows.",
      "page": 5
    },
    {
      "level": "H2",
      "text": "Study 2311E1",
      "page": 5
    },
    {
      "level": "H2",
      "text": "This was a 24-week open-label uncontrolled extension to Study 2311 intended",
      "page": 5
    },
    {
      "level": "H2",
      "text": "primarily to evaluate the safety and tolerability of Exelon® in the study",
      "page": 5
    },
    {
      "level": "H2",
      "text": "population. Patients given the option of enrolling in this study had either",
      "page": 5
    },
    {
      "level": "H2",
      "text": "completed the double-blind treatment phase of Study 2311 or discontinued early",
      "page": 5
    },
    {
      "level": "H2",
      "text": "during that study, but returned for all the remaining scheduled efficacy",
      "page": 5
    },
    {
      "level": "H2",
      "text": "assessments without significant protocol violations. Regardless of their previous",
      "page": 5
    },
    {
      "level": "H2",
      "text": "treatment assignment, patients enrolled in the extension study were all re-titrated",
      "page": 5
    },
    {
      "level": "H2",
      "text": "to a flexible dose of Exelon® that ranged from 1.5 mg BID to 6.0 mg BID, based",
      "page": 5
    },
    {
      "level": "H2",
      "text": "on tolerability.",
      "page": 5
    },
    {
      "level": "H2",
      "text": "433 patients enrolled in Study 2311 were eligible to enroll in Study 2311E1, of",
      "page": 5
    },
    {
      "level": "H2",
      "text": "whom 334 patients actually consented to participate in, and 273 patients,",
      "page": 5
    },
    {
      "level": "H2",
      "text": "completed the latter study.",
      "page": 5
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 6
    },
    {
      "level": "H2",
      "text": "The adverse event profile of Exelon® in Study 2311 was broadly similar to that",
      "page": 6
    },
    {
      "level": "H2",
      "text": "seen in Study 2311E1.",
      "page": 6
    },
    {
      "level": "H2",
      "text": "Non-Interventional Validation Study (Study 2314)",
      "page": 6
    },
    {
      "level": "H2",
      "text": "This 4-week cross-sectional study was intended to evaluate the validity and",
      "page": 6
    },
    {
      "level": "H2",
      "text": "reliability of several measures of cognition, activities of daily living, executive",
      "page": 6
    },
    {
      "level": "H2",
      "text": "function and behavior in patients with Parkinson’s Disease Dementia and",
      "page": 6
    },
    {
      "level": "H2",
      "text": "vascular dementia, and to compare the performance of the same measures in",
      "page": 6
    },
    {
      "level": "H2",
      "text": "those conditions with their performance in Alzheimer’s Disease. This submission",
      "page": 6
    },
    {
      "level": "H2",
      "text": "contains an interim report that only pertains to Parkinson’s Disease Dementia.",
      "page": 6
    },
    {
      "level": "H2",
      "text": "The interim report indicates that 55 patients with Parkinson’s Disease Dementia",
      "page": 6
    },
    {
      "level": "H2",
      "text": "(diagnosed using the DSM-IV criteria) and 58 patients with Alzheimer’s Disease",
      "page": 6
    },
    {
      "level": "H2",
      "text": "(diagnosed using the NINCDS-ADRDA criteria) were enrolled in the study;",
      "page": 6
    },
    {
      "level": "H2",
      "text": "patients with each diagnosis were further grouped into mild and moderate",
      "page": 6
    },
    {
      "level": "H2",
      "text": "categories based on Mini-Mental Status Examination scores of 18 to 24 and 10",
      "page": 6
    },
    {
      "level": "H2",
      "text": "to 17, respectively, at study entry. The efficacy instruments evaluated were the",
      "page": 6
    },
    {
      "level": "H2",
      "text": "ADAS-Cog, Global Deterioration Scale, ADCS-ADL, D-KEFS Verbal Fluency",
      "page": 6
    },
    {
      "level": "H2",
      "text": "Test, Ten-Point Clock Test, Trailmaking Tests A and B, Neuropsychiatry",
      "page": 6
    },
    {
      "level": "H2",
      "text": "Inventory, including Neuropsychiatry Inventory-Distress, and Cognitive Drug",
      "page": 6
    },
    {
      "level": "H2",
      "text": "Research Computerized Assessment System tests for the assessment of",
      "page": 6
    },
    {
      "level": "H2",
      "text": "attention. Each enrolled patient was to be evaluated using these measures at",
      "page": 6
    },
    {
      "level": "H2",
      "text": "baseline and Week 4; all but 2 patients, both in the Parkinson’s Disease",
      "page": 6
    },
    {
      "level": "H2",
      "text": "Dementia group, completed  their evaluations.",
      "page": 6
    },
    {
      "level": "H2",
      "text": "The results of this study have been interpreted as demonstrating the following:",
      "page": 6
    },
    {
      "level": "H1",
      "text": "Conclusions",
      "page": 6
    },
    {
      "level": "H2",
      "text": "Deferred, pending discussion of this application at a scheduled meeting of the",
      "page": 6
    },
    {
      "level": "H2",
      "text": "Peripheral and Central Nervous Systems Drugs Advisory Committee",
      "page": 6
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 7
    },
    {
      "level": "H1",
      "text": "1. Background",
      "page": 7
    },
    {
      "level": "H2",
      "text": "This submission, a Supplemental New Drug Application, seeks the approval of",
      "page": 7
    },
    {
      "level": "H2",
      "text": "Exelon® (rivastigmine tartrate) for the treatment of “mild to moderate dementia",
      "page": 7
    },
    {
      "level": "H2",
      "text": "associated with Parkinson’s Disease.”",
      "page": 7
    },
    {
      "level": "H2",
      "text": "The data supporting this application are stated to be derived entirely from the",
      "page": 7
    },
    {
      "level": "H2",
      "text": "results of the EXPRESS (“Rivastigmine for Dementia Associated with",
      "page": 7
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease”) Study, also referred to as Study 2311. An open-label",
      "page": 7
    },
    {
      "level": "H2",
      "text": "uncontrolled extension to that Study 2311, designated as Study 2311E1 has also",
      "page": 7
    },
    {
      "level": "H2",
      "text": "bee completed.",
      "page": 7
    },
    {
      "level": "H2",
      "text": "A meeting to discuss this submission and the results of the EXPRESS Study was",
      "page": 7
    },
    {
      "level": "H2",
      "text": "held between the Division and sponsor on May 18, 2005, and is summarized",
      "page": 7
    },
    {
      "level": "H2",
      "text": "later in this review.",
      "page": 7
    },
    {
      "level": "H2",
      "text": "Exelon® (rivastigmine tartrate) is an acetylcholinesterase inhibitor drug approved",
      "page": 7
    },
    {
      "level": "H2",
      "text": "by this Agency on April 21, 2000, for the treatment of mild to moderate dementia",
      "page": 7
    },
    {
      "level": "H2",
      "text": "of the Alzheimer’s type, as immediate-release capsule and oral solution",
      "page": 7
    },
    {
      "level": "H2",
      "text": "formulations. Please refer to the primary reviews of NDAs #s 20823 (for the",
      "page": 7
    },
    {
      "level": "H2",
      "text": "immediate-release capsule formulation) and 21025 (for the oral solution",
      "page": 7
    },
    {
      "level": "H2",
      "text": "formulation) for full details.",
      "page": 7
    },
    {
      "level": "H2",
      "text": "In this review, the terms “Exelon®” and “rivastigmine” are used interchangeably.",
      "page": 7
    },
    {
      "level": "H2",
      "text": "Also note that “dementia associated with Parkinson’s Disease” is also referred to,",
      "page": 7
    },
    {
      "level": "H2",
      "text": "apparently interchangeably, as Parkinson’s Disease Dementia (PDD) in the",
      "page": 7
    },
    {
      "level": "H2",
      "text": "sponsor’s submission.",
      "page": 7
    },
    {
      "level": "H2",
      "text": "The Biometrics Reviewer of this submission is Dr Juan (Joanne) Zhang.",
      "page": 7
    },
    {
      "level": "H1",
      "text": "2. Contents Of Submission",
      "page": 7
    },
    {
      "level": "H2",
      "text": "This submission has been provided in accordance, as per the sponsor, with the",
      "page": 7
    },
    {
      "level": "H2",
      "text": "guidance for industry entitled Providing Regulatory Submissions In Electronic",
      "page": 7
    },
    {
      "level": "H2",
      "text": "Format-NDAs (January 1999)",
      "page": 7
    },
    {
      "level": "H2",
      "text": "The key items in this application are:",
      "page": 7
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 8
    },
    {
      "level": "H1",
      "text": "3. Contents Of Review",
      "page": 8
    },
    {
      "level": "H2",
      "text": "The contents of this submission will be addressed under the following principal",
      "page": 8
    },
    {
      "level": "H2",
      "text": "headings and in the same order as below",
      "page": 8
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 9
    },
    {
      "level": "H1",
      "text": "4. Key Diagnostic Instruments Used in Efficacy Study (Study",
      "page": 9
    },
    {
      "level": "H1",
      "text": "2311)",
      "page": 9
    },
    {
      "level": "H2",
      "text": "The criteria for 2 diagnostic instruments used in the efficacy study are listed",
      "page": 9
    },
    {
      "level": "H2",
      "text": "below:",
      "page": 9
    },
    {
      "level": "H1",
      "text": "4.1 UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria",
      "page": 9
    },
    {
      "level": "H1",
      "text": "For Parkinson’s Disease",
      "page": 9
    },
    {
      "level": "H1",
      "text": "Step 1 Diagnosis of Parkinsonian syndrome",
      "page": 9
    },
    {
      "level": "H1",
      "text": "Step 2 Exclusion criteria for Parkinson’s disease",
      "page": 9
    },
    {
      "level": "H1",
      "text": "Step 3 Supportive prospective positive criteria for Parkinson’s disease",
      "page": 9
    },
    {
      "level": "H1",
      "text": "(Three or more required for diagnosis of definite Parkinson’s disease)",
      "page": 9
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 10
    },
    {
      "level": "H1",
      "text": "4.2 DSM-IV Criteria For Dementia Due To Parkinson’s Disease",
      "page": 10
    },
    {
      "level": "H2",
      "text": "294.1    Dementia Due To Parkinson’s Disease",
      "page": 10
    },
    {
      "level": "H2",
      "text": "The essential feature of Dementia Due To Parkinson’s Disease is the presence of dementia that is judged to be of",
      "page": 10
    },
    {
      "level": "H2",
      "text": "direct pathophysiological consequence of Parkinson’s disease. Parkinson’s disease is a slowly progressive",
      "page": 10
    },
    {
      "level": "H2",
      "text": "neurological condition, characterized by tremor, rigidity, bradykinesia, and postural instability. Dementia has been",
      "page": 10
    },
    {
      "level": "H2",
      "text": "reported to occur in approximately 20%-60% of individuals with Parkinson’s disease and is more likely to be present in",
      "page": 10
    },
    {
      "level": "H2",
      "text": "older individuals or in those with more severe or advanced disease. The dementia associated with Parkinson’s disease",
      "page": 10
    },
    {
      "level": "H2",
      "text": "is characterized by cognitive and motor slowing, executive dysfunction and impairment in memory retrieval. Declining",
      "page": 10
    },
    {
      "level": "H2",
      "text": "cognitive performance in individuals with Parkinson’s disease is frequently exacerbated by depression. Findings on",
      "page": 10
    },
    {
      "level": "H2",
      "text": "physical examination include the characteristic abnormal motor signs of resting tremor, evidence of slowness and",
      "page": 10
    },
    {
      "level": "H2",
      "text": "poverty of movement (such as micrographia), or muscular rigidity and loss of associated movements. At autopsy,",
      "page": 10
    },
    {
      "level": "H2",
      "text": "neuronal loss and Lewy bodies are evident in the substantia nigra. There are a number of syndromes that manifest",
      "page": 10
    },
    {
      "level": "H2",
      "text": "with dementia, Parkinsonian movement disorders, and additional neurological features (e.g., progressive supranuclear",
      "page": 10
    },
    {
      "level": "H2",
      "text": "palsy, olivopontocerebellar degeneration, and Vascular Dementia). Some individuals with Parkinson’s disease and",
      "page": 10
    },
    {
      "level": "H2",
      "text": "dementia are found at autopsy to have coexisting neuropathology indicative of Alzheimer’s disease or of diffuse Lewy",
      "page": 10
    },
    {
      "level": "H2",
      "text": "body disease.",
      "page": 10
    },
    {
      "level": "H1",
      "text": "5. Efficacy Outcome Measures And Selected Additional",
      "page": 10
    },
    {
      "level": "H1",
      "text": "Instruments Used In Efficacy Study",
      "page": 10
    },
    {
      "level": "H2",
      "text": "These instruments are outlined below:",
      "page": 10
    },
    {
      "level": "H1",
      "text": "5.1 Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-",
      "page": 10
    },
    {
      "level": "H1",
      "text": "Cog)",
      "page": 10
    },
    {
      "level": "H2",
      "text": "This is a validated instrument  consisting of the following 11 items: Word Recall",
      "page": 10
    },
    {
      "level": "H2",
      "text": "Task, Naming Fingers and Objects, Orientation Questions, Constructional Praxis",
      "page": 10
    },
    {
      "level": "H2",
      "text": "Task, Following Commands, Ideational Praxis Task, Word Recognition Task,",
      "page": 10
    },
    {
      "level": "H2",
      "text": "Rating of Spoken Language, Rating of Language Comprehension, Rating of",
      "page": 10
    },
    {
      "level": "H2",
      "text": "Word Finding Difficulty and Rating of Ability to Recall Test Instructions. The total",
      "page": 10
    },
    {
      "level": "H2",
      "text": "scores range from 0-70 with higher scores indicating greater cognitive",
      "page": 10
    },
    {
      "level": "H2",
      "text": "impairment.",
      "page": 10
    },
    {
      "level": "H1",
      "text": "5.2 Alzheimer’s Disease Cooperative Study – Clinician’s Global Impression",
      "page": 10
    },
    {
      "level": "H1",
      "text": "Of Change (ADCS-CGIC)",
      "page": 10
    },
    {
      "level": "H2",
      "text": "This instrument provides for a rating of overall (global) change from baseline by",
      "page": 10
    },
    {
      "level": "H2",
      "text": "an independent clinician experienced in the assessment of patients with",
      "page": 10
    },
    {
      "level": "H2",
      "text": "dementia. The term “independent” implies that the rater is not to be involved in",
      "page": 10
    },
    {
      "level": "H2",
      "text": "any additional manner in the evaluation and/or treatment of patients enrolled in",
      "page": 10
    },
    {
      "level": "H2",
      "text": "this study",
      "page": 10
    },
    {
      "level": "H2",
      "text": "Assessments will be performed at baseline and at subsequent visits. It is",
      "page": 10
    },
    {
      "level": "H2",
      "text": "recommended that the baseline interview be conducted by 2 independent raters,",
      "page": 10
    },
    {
      "level": "H2",
      "text": "one designated as the primary rater and the other as a backup. Post-baseline",
      "page": 10
    },
    {
      "level": "H2",
      "text": "ratings are to be conducted solely by the primary rater or, in his/her absence, by",
      "page": 10
    },
    {
      "level": "H2",
      "text": "the back-up rater.",
      "page": 10
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 11
    },
    {
      "level": "H2",
      "text": "At baseline both raters will have access to all of the patients’ available records",
      "page": 11
    },
    {
      "level": "H2",
      "text": "and evaluations. At all subsequent visits, the rater is to rely (for baseline data)",
      "page": 11
    },
    {
      "level": "H2",
      "text": "solely upon information obtained during the baseline assessment of the patient",
      "page": 11
    },
    {
      "level": "H2",
      "text": "and caregiver by that rater (including written notes and, if available, the baseline",
      "page": 11
    },
    {
      "level": "H2",
      "text": "interview audiotape or videotape). At post-baseline visits, data obtained directly",
      "page": 11
    },
    {
      "level": "H2",
      "text": "from the patient may be supplemented by that obtained from the caregiver. The",
      "page": 11
    },
    {
      "level": "H2",
      "text": "rater will not have access to other safety or efficacy data, including all previous",
      "page": 11
    },
    {
      "level": "H2",
      "text": "post-baseline ADCS-CGIC ratings by either rater.",
      "page": 11
    },
    {
      "level": "H2",
      "text": "A standard 7-point categorical rating scale and its dichotomized version will both",
      "page": 11
    },
    {
      "level": "H2",
      "text": "be used for rating and are further described below:",
      "page": 11
    },
    {
      "level": "H3",
      "text": "Change",
      "page": 11
    },
    {
      "level": "H3",
      "text": "Rating",
      "page": 11
    },
    {
      "level": "H3",
      "text": "Rating On 7-Point Scale",
      "page": 11
    },
    {
      "level": "H3",
      "text": "Rating On Dichotomized Scale",
      "page": 11
    },
    {
      "level": "H2",
      "text": "The format for assessment is semi-structured with a guideline provided for",
      "page": 11
    },
    {
      "level": "H2",
      "text": "assessing the global impression of change based on ratings of change for the",
      "page": 11
    },
    {
      "level": "H2",
      "text": "following individual domains: cognition, behavior, and function.",
      "page": 11
    },
    {
      "level": "H2",
      "text": "A semi-structured format for assessing the severity of disease at baseline has",
      "page": 11
    },
    {
      "level": "H2",
      "text": "also been used, again with a guideline provided for assessing the global",
      "page": 11
    },
    {
      "level": "H2",
      "text": "impression of severity based on ratings of change for the following individual",
      "page": 11
    },
    {
      "level": "H2",
      "text": "domains: cognition, behavior, and function.",
      "page": 11
    },
    {
      "level": "H1",
      "text": "5.3 Alzheimer’s Disease Cooperative Study – Activities Of Daily Living",
      "page": 11
    },
    {
      "level": "H1",
      "text": "Scale (ADCS-ADL)",
      "page": 11
    },
    {
      "level": "H2",
      "text": "This is a rating scale used to assess basic and instrumental activities of daily",
      "page": 11
    },
    {
      "level": "H2",
      "text": "living.  23 items are rated by the investigator using information supplied by the",
      "page": 11
    },
    {
      "level": "H2",
      "text": "caregiver. The maximum total score is 78. Higher scores indicate better function.",
      "page": 11
    },
    {
      "level": "H1",
      "text": "5.4 Cognitive Drug Research Computerized Assessment System",
      "page": 11
    },
    {
      "level": "H2",
      "text": "This is a computer-based system for assessing cognitive function. A series of",
      "page": 11
    },
    {
      "level": "H2",
      "text": "tasks is used to assess each of several specific functions as indicated in the",
      "page": 11
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 12
    },
    {
      "level": "H2",
      "text": "table below. Only Level I (Attention) is assessed in the study contained in this",
      "page": 12
    },
    {
      "level": "H2",
      "text": "submission.",
      "page": 12
    },
    {
      "level": "H3",
      "text": "Level",
      "page": 12
    },
    {
      "level": "H2",
      "text": "A description of each of the tests at Level I is presented below",
      "page": 12
    },
    {
      "level": "H3",
      "text": "Test",
      "page": 12
    },
    {
      "level": "H3",
      "text": "Simple Reaction Time",
      "page": 12
    },
    {
      "level": "H3",
      "text": "Digit Vigilance Task",
      "page": 12
    },
    {
      "level": "H3",
      "text": "Choice Reaction Time",
      "page": 12
    },
    {
      "level": "H1",
      "text": "5.5 Delis-Kaplan Executive Functioning System (D-KEFS) Test Battery",
      "page": 12
    },
    {
      "level": "H2",
      "text": "This test battery assesses verbal and non-verbal executive functions. 9 tests are",
      "page": 12
    },
    {
      "level": "H2",
      "text": "included in this battery; each test is intended to be used as either a stand-alone",
      "page": 12
    },
    {
      "level": "H2",
      "text": "instrument or in conjunction with other tests in the same battery. The tests are as",
      "page": 12
    },
    {
      "level": "H2",
      "text": "follows: Trail Making Test, Verbal Fluency Test, Design Fluency Test, Color-",
      "page": 12
    },
    {
      "level": "H2",
      "text": "Word Interference Test, Sorting Test (formerly called the California Card Sorting",
      "page": 12
    },
    {
      "level": "H2",
      "text": "Test), Twenty Questions Test, Word Context Test, Tower Test, and Proverb Test",
      "page": 12
    },
    {
      "level": "H2",
      "text": "(formerly called the California Proverb Test).",
      "page": 12
    },
    {
      "level": "H2",
      "text": "Only the Verbal Fluency Test from this battery was eventually used as a uniform",
      "page": 12
    },
    {
      "level": "H2",
      "text": "outcome measure for this study; only one condition of this test, letter fluency, was",
      "page": 12
    },
    {
      "level": "H2",
      "text": "used; here the patient was asked to generate as many words as possible for 3",
      "page": 12
    },
    {
      "level": "H2",
      "text": "different letters of the alphabet (“F,” “A,” and “S,”) with 60 seconds being allowed",
      "page": 12
    },
    {
      "level": "H2",
      "text": "for each alphabet tested. 2 other tests, the Sorting Test and the Color-Word",
      "page": 12
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 13
    },
    {
      "level": "H2",
      "text": "Interference Test were used at selected centers.  The main outcome variable for",
      "page": 13
    },
    {
      "level": "H2",
      "text": "each of these measures is listed below:",
      "page": 13
    },
    {
      "level": "H3",
      "text": "Test",
      "page": 13
    },
    {
      "level": "H3",
      "text": "Main Outcome Variable",
      "page": 13
    },
    {
      "level": "H1",
      "text": "5.6 Mini-Mental Status Examination",
      "page": 13
    },
    {
      "level": "H2",
      "text": "This is a validated multi-item instrument that examines orientation, registration,",
      "page": 13
    },
    {
      "level": "H2",
      "text": "attention, calculation, recall, visuospatial abilities and language. The maximum",
      "page": 13
    },
    {
      "level": "H2",
      "text": "score is 30, with higher scores indicating better cognitive function.",
      "page": 13
    },
    {
      "level": "H1",
      "text": "5.7 Neuropsychiatry Inventory",
      "page": 13
    },
    {
      "level": "H2",
      "text": "This is a validated instrument that assesses the following 12 domains",
      "page": 13
    },
    {
      "level": "H2",
      "text": "(subscales): delusions, hallucinations, agitation/aggression,",
      "page": 13
    },
    {
      "level": "H2",
      "text": "depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition,",
      "page": 13
    },
    {
      "level": "H2",
      "text": "irritability/lability, aberrant motor behavior, sleep/night-time behavior, and",
      "page": 13
    },
    {
      "level": "H2",
      "text": "appetite/eating changes . Each domain is rated according to its frequency (score",
      "page": 13
    },
    {
      "level": "H2",
      "text": "ranging from 1 to 4) and severity (score ranging from 1 to 3); rating is based on",
      "page": 13
    },
    {
      "level": "H2",
      "text": "interviewing a caregiver; if a symptom subsumed by a particular domain is",
      "page": 13
    },
    {
      "level": "H2",
      "text": "absent, it will receive a rating of 0. For each domain, the score is the product of",
      "page": 13
    },
    {
      "level": "H2",
      "text": "frequency and severity, with a maximum score of 12. The maximum total score",
      "page": 13
    },
    {
      "level": "H2",
      "text": "for the 12 domains (the sum of the subscale scores) is 144 with a higher score",
      "page": 13
    },
    {
      "level": "H2",
      "text": "indicating greater behavioral abnormality.",
      "page": 13
    },
    {
      "level": "H2",
      "text": "An earlier version of the Neuropsychiatry Inventory (Neuropsychiatry Inventory-",
      "page": 13
    },
    {
      "level": "H2",
      "text": "10), consisting of the first 10 items above, and with a maximum total score of 100",
      "page": 13
    },
    {
      "level": "H2",
      "text": "has also been used.",
      "page": 13
    },
    {
      "level": "H2",
      "text": "5.7.1 Neuropsychiatry Inventory – Distress",
      "page": 13
    },
    {
      "level": "H2",
      "text": "For each of the 12 items on the Neuropsychiatry Inventory, caregiver distress is",
      "page": 13
    },
    {
      "level": "H2",
      "text": "rated on a 5-point scale from 1 to 5, with higher scores indicating greater",
      "page": 13
    },
    {
      "level": "H2",
      "text": "distress.",
      "page": 13
    },
    {
      "level": "H1",
      "text": "5.8 Ten-Point Clock Test",
      "page": 13
    },
    {
      "level": "H2",
      "text": "This test is intended to measure executive functioning and visuospatial skills. The",
      "page": 13
    },
    {
      "level": "H2",
      "text": "subject is asked to insert the numbers on the face of the clock and when that",
      "page": 13
    },
    {
      "level": "H2",
      "text": "task is completed to insert the hands of the clock so as to indicate a time of ten",
      "page": 13
    },
    {
      "level": "H2",
      "text": "minutes past eleven o’clock. The maximum score on this task is 10, with lower",
      "page": 13
    },
    {
      "level": "H2",
      "text": "scores indicating greater degrees of impairment",
      "page": 13
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 14
    },
    {
      "level": "H1",
      "text": "5.9 Symbol-Digit Modalities Test",
      "page": 14
    },
    {
      "level": "H2",
      "text": "This test is intended to measure information processing speed and attention.",
      "page": 14
    },
    {
      "level": "H2",
      "text": "Subjects match numbers to symbols using a key; the symbols are printed and the",
      "page": 14
    },
    {
      "level": "H2",
      "text": "numbers written in by the subject. 110 items are to be filled in a period of 90",
      "page": 14
    },
    {
      "level": "H2",
      "text": "seconds.",
      "page": 14
    },
    {
      "level": "H1",
      "text": "5.10 Health Economic Parameters",
      "page": 14
    },
    {
      "level": "H2",
      "text": "These are to include the following",
      "page": 14
    },
    {
      "level": "H1",
      "text": "5.11 Unified Parkinson’s Disease Rating Scale (UPDRS)",
      "page": 14
    },
    {
      "level": "H2",
      "text": "This is a composite scale intended for rating patients with Parkinson’s Disease.",
      "page": 14
    },
    {
      "level": "H2",
      "text": "The scale is composed of 6 sections, each of which is rated categorically",
      "page": 14
    },
    {
      "level": "H3",
      "text": "Part",
      "page": 14
    },
    {
      "level": "H2",
      "text": "Individual items are rated as follows",
      "page": 14
    },
    {
      "level": "H2",
      "text": "Part III of this scale (Motor Examination) will be used as an outcome measure in",
      "page": 14
    },
    {
      "level": "H2",
      "text": "this study. The individual items in Part III are",
      "page": 14
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 15
    },
    {
      "level": "H1",
      "text": "6. Summary Of Key Efficacy Study (EXPRESS Study; Study",
      "page": 15
    },
    {
      "level": "H1",
      "text": "2311)",
      "page": 15
    },
    {
      "level": "H2",
      "text": "The study protocol and main efficacy results for this study are summarized",
      "page": 15
    },
    {
      "level": "H2",
      "text": "below.",
      "page": 15
    },
    {
      "level": "H1",
      "text": "6.1 Outline",
      "page": 15
    },
    {
      "level": "H2",
      "text": "The study outline is below",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Design",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Duration",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Key Inclusion Criteria",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Primary Efficacy Measures",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Population For Primary Efficacy Analysis",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Secondary Efficacy Measures",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Safety Measures",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Dose Arms",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Number randomized",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Number completing",
      "page": 15
    },
    {
      "level": "H1",
      "text": "6.2 Results Of Primary Efficacy Analysis",
      "page": 15
    },
    {
      "level": "H2",
      "text": "The results of the primary efficacy analysis as performed on the intent-to-treat",
      "page": 15
    },
    {
      "level": "H2",
      "text": "plus retrieved dropout population is summarized below",
      "page": 15
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 16
    },
    {
      "level": "H3",
      "text": "ADAS-Cog change from baseline to Week 24",
      "page": 16
    },
    {
      "level": "H3",
      "text": "ADCS-CGIC at Week 24",
      "page": 16
    },
    {
      "level": "H3",
      "text": "*95% confidence interval: 1.44 to 4.31",
      "page": 16
    },
    {
      "level": "H1",
      "text": "7. Description Of Efficacy Study 2311 (EXPRESS Study)",
      "page": 16
    },
    {
      "level": "H2",
      "text": "This study was conducted outside the purview of an IND application, and the",
      "page": 16
    },
    {
      "level": "H2",
      "text": "protocol was not submitted to this Division for review prior to the study being",
      "page": 16
    },
    {
      "level": "H2",
      "text": "conducted or at any time while the study was ongoing.",
      "page": 16
    },
    {
      "level": "H2",
      "text": "Note that the results of this study have also been published. The abstract of that",
      "page": 16
    },
    {
      "level": "H2",
      "text": "publication has been provided later in this section",
      "page": 16
    },
    {
      "level": "H1",
      "text": "7.1 Protocol",
      "page": 16
    },
    {
      "level": "H1",
      "text": "The protocol described below is the final version",
      "page": 16
    },
    {
      "level": "H2",
      "text": "7.1.1 Title",
      "page": 16
    },
    {
      "level": "H2",
      "text": "A 24-Week, Prospective, Randomized, Multicenter, Double-Blind, Placebo-",
      "page": 16
    },
    {
      "level": "H2",
      "text": "Controlled, Parallel-Group Study Of the Efficacy, Tolerability, And Safety Of 3 –",
      "page": 16
    },
    {
      "level": "H2",
      "text": "12 Mg/Day Of Exelon® (Rivastigmine) Capsules In Patients With Parkinson’s",
      "page": 16
    },
    {
      "level": "H2",
      "text": "Disease Dementia",
      "page": 16
    },
    {
      "level": "H2",
      "text": "7.1.2 Objectives",
      "page": 16
    },
    {
      "level": "H2",
      "text": "7.1.2.1 Primary",
      "page": 16
    },
    {
      "level": "H2",
      "text": "To evaluate the efficacy of Exelon® (3 to 12 mg/day) compared with placebo for",
      "page": 16
    },
    {
      "level": "H2",
      "text": "a treatment period of 24 weeks in patients with Parkinson’s Disease Dementia.",
      "page": 16
    },
    {
      "level": "H2",
      "text": "Efficacy will be evaluated on the following:",
      "page": 16
    },
    {
      "level": "H2",
      "text": "7.1.2.2 Secondary",
      "page": 16
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 17
    },
    {
      "level": "H2",
      "text": "7.1.3 Design, Duration, Sample Size, Dosage",
      "page": 17
    },
    {
      "level": "H2",
      "text": "This was to be a 24-week randomized, double-blind, placebo-controlled, parallel-",
      "page": 17
    },
    {
      "level": "H2",
      "text": "arm study.",
      "page": 17
    },
    {
      "level": "H2",
      "text": "About 540 patients were to be randomized 2:1 to Exelon® or placebo (i.e., about",
      "page": 17
    },
    {
      "level": "H2",
      "text": "360 patients to Exelon® and about 180 patients to placebo).",
      "page": 17
    },
    {
      "level": "H2",
      "text": "The overall study design is summarized in the following table:",
      "page": 17
    },
    {
      "level": "H2",
      "text": "4 dose levels were to be used for Exelon® (and for matching placebo). The dose",
      "page": 17
    },
    {
      "level": "H2",
      "text": "levels for Exelon® are shown in the following table",
      "page": 17
    },
    {
      "level": "H3",
      "text": "Dose Level",
      "page": 17
    },
    {
      "level": "H2",
      "text": "The actual dosing regime was to be as follows:",
      "page": 17
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 18
    },
    {
      "level": "H2",
      "text": "• For the maintenance period",
      "page": 18
    },
    {
      "level": "H2",
      "text": "After completing the double-blind phase, patients were to have the option of",
      "page": 18
    },
    {
      "level": "H2",
      "text": "receiving open-label treatment for up to 6 months.",
      "page": 18
    },
    {
      "level": "H2",
      "text": "Note that the Exelon® dose range proposed for use in this trial was identical to",
      "page": 18
    },
    {
      "level": "H2",
      "text": "that used in clinical trials in Alzheimer’s Disease.",
      "page": 18
    },
    {
      "level": "H2",
      "text": "7.1.4 Selection",
      "page": 18
    },
    {
      "level": "H2",
      "text": "7.1.4.1 Key Inclusion Criteria",
      "page": 18
    },
    {
      "level": "H2",
      "text": "7.1.4.2 Key Exclusion Criteria",
      "page": 18
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 19
    },
    {
      "level": "H2",
      "text": "• Any disability that interferes with completion of study requirements",
      "page": 19
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 20
    },
    {
      "level": "H2",
      "text": "7.1.4.3 Concomitant Medications",
      "page": 20
    },
    {
      "level": "H2",
      "text": "7.1.4.3.1 Prohibited",
      "page": 20
    },
    {
      "level": "H2",
      "text": "7.1.4.3.2 Permitted (With Limitations)",
      "page": 20
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 21
    },
    {
      "level": "H2",
      "text": "7.1.5 Schedule",
      "page": 21
    },
    {
      "level": "H2",
      "text": "The study schedule is summarized in the following table, which I have copied",
      "page": 21
    },
    {
      "level": "H2",
      "text": "from the submission.",
      "page": 21
    },
    {
      "level": "H1",
      "text": "Note that brain imaging (i.e., computerized tomography or magnetic",
      "page": 21
    },
    {
      "level": "H1",
      "text": "resonance scanning) was not required prior to entry into the study.",
      "page": 21
    },
    {
      "level": "H2",
      "text": "Special diagnostic laboratory tests at screening included serum TSH, folic acid,",
      "page": 21
    },
    {
      "level": "H2",
      "text": "Vitamin B12 and RPR.",
      "page": 21
    },
    {
      "level": "H2",
      "text": "Also note the following",
      "page": 21
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 22
    },
    {
      "level": "H2",
      "text": "7.1.6 Outcome Measures",
      "page": 22
    },
    {
      "level": "H2",
      "text": "7.1.6.1 Primary Efficacy Measures",
      "page": 22
    },
    {
      "level": "H2",
      "text": "7.1.6.2 Secondary Efficacy Measures",
      "page": 22
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 23
    },
    {
      "level": "H2",
      "text": "7.1.6.3 Safety Measures",
      "page": 23
    },
    {
      "level": "H2",
      "text": "Adverse events, safety laboratory tests, vital signs, body weight,",
      "page": 23
    },
    {
      "level": "H2",
      "text": "electrocardiograms, and UPDRS Part III",
      "page": 23
    },
    {
      "level": "H2",
      "text": "7.1.7 Safety Monitoring",
      "page": 23
    },
    {
      "level": "H2",
      "text": "Adverse events, safety laboratory tests, vital signs, body weight,",
      "page": 23
    },
    {
      "level": "H2",
      "text": "electrocardiograms, and UPDRS Part III",
      "page": 23
    },
    {
      "level": "H2",
      "text": "7.1.8 Analysis Plan",
      "page": 23
    },
    {
      "level": "H2",
      "text": "7.1.8.1 General",
      "page": 23
    },
    {
      "level": "H2",
      "text": "The data from each center were intended to be pooled with data from other",
      "page": 23
    },
    {
      "level": "H2",
      "text": "centers so that an adequate number of patients would be available for analysis.",
      "page": 23
    },
    {
      "level": "H2",
      "text": "Unless otherwise specified, all statistical tests were to be conducted using a two-",
      "page": 23
    },
    {
      "level": "H2",
      "text": "sided Type I error of 0.05.",
      "page": 23
    },
    {
      "level": "H2",
      "text": "7.1.8.2 Study Populations",
      "page": 23
    },
    {
      "level": "H2",
      "text": "7.1.8.2.1 Intent-To-Treat With Retrieved Dropouts",
      "page": 23
    },
    {
      "level": "H2",
      "text": "This population was to include all randomized patients who received at least one",
      "page": 23
    },
    {
      "level": "H2",
      "text": "dose of study medication and had at least a pre- and post-baseline assessment",
      "page": 23
    },
    {
      "level": "H2",
      "text": "for one of the primary efficacy variables.",
      "page": 23
    },
    {
      "level": "H2",
      "text": "The imputation scheme that was to be used to create a score for every",
      "page": 23
    },
    {
      "level": "H2",
      "text": "randomized subject is described as follows in the study protocol: If available, the",
      "page": 23
    },
    {
      "level": "H2",
      "text": "endpoint assessment is used; if missing, the retrieved dropout assessment is",
      "page": 23
    },
    {
      "level": "H2",
      "text": "used; if the retrieved dropout assessment is unavailable, the last observation",
      "page": 23
    },
    {
      "level": "H2",
      "text": "available on the subject is used.",
      "page": 23
    },
    {
      "level": "H2",
      "text": "7.1.8.2.2 Intent-To-Treat-Last-Observation-Carried-Forward",
      "page": 23
    },
    {
      "level": "H2",
      "text": "This population was to include all randomized patients who received at least one",
      "page": 23
    },
    {
      "level": "H2",
      "text": "dose of study medication and had at least a pre- and post-baseline assessment",
      "page": 23
    },
    {
      "level": "H2",
      "text": "for one of the primary efficacy variables.",
      "page": 23
    },
    {
      "level": "H2",
      "text": "The imputation scheme that was to be used to create a score for every",
      "page": 23
    },
    {
      "level": "H2",
      "text": "randomized subject is described as follows in the study protocol: If available, the",
      "page": 23
    },
    {
      "level": "H2",
      "text": "endpoint assessment is used; if missing, the immediate preceding observation",
      "page": 23
    },
    {
      "level": "H2",
      "text": "available, scheduled or unscheduled, is utilized, provided that the assessment is",
      "page": 23
    },
    {
      "level": "H2",
      "text": "made while the subject is still considered to be a participant in the study, i.e., at",
      "page": 23
    },
    {
      "level": "H2",
      "text": "most 2 days after the last dose of study medication.",
      "page": 23
    },
    {
      "level": "H2",
      "text": "7.1.8.2.3 Observed Cases",
      "page": 23
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 24
    },
    {
      "level": "H2",
      "text": "This population was to consist of all randomized patients who had an evaluation",
      "page": 24
    },
    {
      "level": "H2",
      "text": "on treatment at the designated assessment time (either interim scheduled or",
      "page": 24
    },
    {
      "level": "H2",
      "text": "endpoint). Evaluations done more than 2 days after the last dose of study",
      "page": 24
    },
    {
      "level": "H2",
      "text": "medication were not to be included. No imputation is involved with this population",
      "page": 24
    },
    {
      "level": "H2",
      "text": "7.1.8.2.4 Safety Population",
      "page": 24
    },
    {
      "level": "H2",
      "text": "This population was to consist of all patients who have received at least one",
      "page": 24
    },
    {
      "level": "H2",
      "text": "dose of study medication and had at least one safety assessment after baseline.",
      "page": 24
    },
    {
      "level": "H2",
      "text": "7.1.8.3 Demographic And Other Baseline Characteristics",
      "page": 24
    },
    {
      "level": "H2",
      "text": "7.1.8.4 Study Medications",
      "page": 24
    },
    {
      "level": "H2",
      "text": "Descriptive statistics for study drug exposure by treatment and data listings for",
      "page": 24
    },
    {
      "level": "H2",
      "text": "study drug doses administered were also to be provided",
      "page": 24
    },
    {
      "level": "H2",
      "text": "7.1.8.5 Concomitant Therapy",
      "page": 24
    },
    {
      "level": "H2",
      "text": "Descriptive statistics (frequency counts and percentages) for concomitant",
      "page": 24
    },
    {
      "level": "H2",
      "text": "medication were to be presented by treatment group for patients in the safety",
      "page": 24
    },
    {
      "level": "H2",
      "text": "population",
      "page": 24
    },
    {
      "level": "H2",
      "text": "7.1.8.6 Primary Efficacy Parameters",
      "page": 24
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 25
    },
    {
      "level": "H2",
      "text": "7.1.8.7 Secondary Efficacy Parameters And Additional Analyses",
      "page": 25
    },
    {
      "level": "H2",
      "text": "Secondary efficacy variables were to be analyzed using an analysis of",
      "page": 25
    },
    {
      "level": "H2",
      "text": "covariance model with treatment, country, and the corresponding baseline",
      "page": 25
    },
    {
      "level": "H2",
      "text": "measurement as the covariates.",
      "page": 25
    },
    {
      "level": "H2",
      "text": "Secondary efficacy analyses of the primary efficacy variables were to be",
      "page": 25
    },
    {
      "level": "H2",
      "text": "performed on population subgroups defined by the presence of impaired",
      "page": 25
    },
    {
      "level": "H2",
      "text": "attention and concentration on the baseline attentional task scores of the",
      "page": 25
    },
    {
      "level": "H2",
      "text": "Cognitive Drug Research computerized battery.",
      "page": 25
    },
    {
      "level": "H2",
      "text": "7.1.8.8 Safety Parameters",
      "page": 25
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 26
    },
    {
      "level": "H2",
      "text": "7.1.8.9 Sample Size Rationale",
      "page": 26
    },
    {
      "level": "H2",
      "text": "Sample size estimates were performed using the two primary efficacy",
      "page": 26
    },
    {
      "level": "H2",
      "text": "parameters the ADAS-Cog and the ADCS-CGIC, and is further summarized",
      "page": 26
    },
    {
      "level": "H2",
      "text": "below",
      "page": 26
    },
    {
      "level": "H2",
      "text": "7.1.8.9.1 Sample Size Estimate Based On ADAS-Cog",
      "page": 26
    },
    {
      "level": "H2",
      "text": "Estimates of standard deviation from the intent-to-treat analysis of 6-month",
      "page": 26
    },
    {
      "level": "H2",
      "text": "change from baseline ADAS-Cog data in clinical trials of Exelon® in Alzheimer’s",
      "page": 26
    },
    {
      "level": "H2",
      "text": "Disease range from 6 to 7 points",
      "page": 26
    },
    {
      "level": "H2",
      "text": "To ensure adequate power in case of a higher variability in 6-month change from",
      "page": 26
    },
    {
      "level": "H2",
      "text": "baseline ADAS-Cog scores in those with Parkinson’s Disease as compared with",
      "page": 26
    },
    {
      "level": "H2",
      "text": "those with Alzheimer’s Disease, a standard deviation of 7.5 points was assumed",
      "page": 26
    },
    {
      "level": "H2",
      "text": "for this sample size estimate",
      "page": 26
    },
    {
      "level": "H2",
      "text": "Using a two-sided test with a significance level of 0.05, and a pooled standard",
      "page": 26
    },
    {
      "level": "H2",
      "text": "deviation of 7.5 points, a total sample size of 531 patients (354 on Exelon® and",
      "page": 26
    },
    {
      "level": "H2",
      "text": "177 on placebo) is required to detect a difference of at least 2.25 points in the",
      "page": 26
    },
    {
      "level": "H2",
      "text": "ADAS-Cog change from baseline score between Exelon® and placebo with a",
      "page": 26
    },
    {
      "level": "H2",
      "text": "power of 90%.",
      "page": 26
    },
    {
      "level": "H2",
      "text": "7.1.8.9.2 Sample Size Estimate Based On ADCS-CGIC",
      "page": 26
    },
    {
      "level": "H2",
      "text": "Assumptions regarding the variability and treatment differences for the ADCS-",
      "page": 26
    },
    {
      "level": "H2",
      "text": "CGIC are based on data available for the CIBIC-Plus from completed Exelon®",
      "page": 26
    },
    {
      "level": "H2",
      "text": "studies in Alzheimer’s Disease; the ADCS-CGIC and CIBIC-Plus are very similar",
      "page": 26
    },
    {
      "level": "H2",
      "text": "instruments.",
      "page": 26
    },
    {
      "level": "H2",
      "text": "To ensure adequate power in case of a higher variability in ADCS-CGIC scores",
      "page": 26
    },
    {
      "level": "H2",
      "text": "in those with Parkinson’s Disease as compared with those with Alzheimer’s",
      "page": 26
    },
    {
      "level": "H2",
      "text": "Disease, a standard deviation of 1.3 points was assumed  for this sample size",
      "page": 26
    },
    {
      "level": "H2",
      "text": "estimate",
      "page": 26
    },
    {
      "level": "H2",
      "text": "Using a two-sided test with a significance level of 0.05, and a pooled standard",
      "page": 26
    },
    {
      "level": "H2",
      "text": "deviation of 1.3 points, a total sample size of 525 patients (350 on Exelon® and",
      "page": 26
    },
    {
      "level": "H2",
      "text": "175 on placebo) is required to detect a difference of at least 0.40 points on the",
      "page": 26
    },
    {
      "level": "H2",
      "text": "intent-to-treat analysis in the ADCS-CGIC score at Month 6 between Exelon®",
      "page": 26
    },
    {
      "level": "H2",
      "text": "and placebo with a power of 90%.",
      "page": 26
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 27
    },
    {
      "level": "H2",
      "text": "7.1.8.9.3 Overall Sample Size Estimate",
      "page": 27
    },
    {
      "level": "H2",
      "text": "To ensure that the study has adequate power to detect statistically significant",
      "page": 27
    },
    {
      "level": "H2",
      "text": "results for both primary efficacy variables, 540 patients were to be enrolled.",
      "page": 27
    },
    {
      "level": "H1",
      "text": "7.2 Study Results",
      "page": 27
    },
    {
      "level": "H2",
      "text": "The study was conducted in Austria, Belgium, Canada, France, Germany, Italy,",
      "page": 27
    },
    {
      "level": "H2",
      "text": "the Netherlands, Norway, Portugal, Spain, Turkey, and the United Kingdom,",
      "page": 27
    },
    {
      "level": "H2",
      "text": "between October 10, 2002, and January 20, 2004.",
      "page": 27
    },
    {
      "level": "H2",
      "text": "A total of 68 centers participated in the study.",
      "page": 27
    },
    {
      "level": "H2",
      "text": "7.2.1 Patient Disposition",
      "page": 27
    },
    {
      "level": "H2",
      "text": "A total of 650 patients were screened, of whom 541 were randomized, 362 to the",
      "page": 27
    },
    {
      "level": "H2",
      "text": "Exelon® group and 179 to the placebo.",
      "page": 27
    },
    {
      "level": "H2",
      "text": "As the above sponsor table indicates, a total of 410 patients (263 [72.7%] who",
      "page": 27
    },
    {
      "level": "H2",
      "text": "received Exelon®, and 147 [82.1%] who received placebo, completed the study).",
      "page": 27
    },
    {
      "level": "H2",
      "text": "As the table above also indicates, the majority of discontinuations were due to",
      "page": 27
    },
    {
      "level": "H2",
      "text": "adverse events: 17.1% of patients in the Exelon® group and 7.8% of patients in",
      "page": 27
    },
    {
      "level": "H2",
      "text": "the placebo group discontinued on account of adverse events.",
      "page": 27
    },
    {
      "level": "H2",
      "text": "7.2.2 Protocol Deviations",
      "page": 27
    },
    {
      "level": "H2",
      "text": "Protocol violations are summarized in the following table, which I have copied",
      "page": 27
    },
    {
      "level": "H2",
      "text": "from the submission.",
      "page": 27
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 28
    },
    {
      "level": "H2",
      "text": "The table indicates that protocol violations were slightly more frequent in the",
      "page": 28
    },
    {
      "level": "H2",
      "text": "Exelon® group than in the placebo group. The most common protocol violation",
      "page": 28
    },
    {
      "level": "H2",
      "text": "was an increase in dose or the new introduction of a psychotropic or",
      "page": 28
    },
    {
      "level": "H2",
      "text": "dopaminergic medication; this category of violation was about equal in incidence",
      "page": 28
    },
    {
      "level": "H2",
      "text": "between the treatment groups.",
      "page": 28
    },
    {
      "level": "H2",
      "text": "7.2.3 Groupings For Analysis",
      "page": 28
    },
    {
      "level": "H2",
      "text": "The groupings for analysis are summarized in the following sponsor table.",
      "page": 28
    },
    {
      "level": "H3",
      "text": "ITT: Intent-to-treat",
      "page": 28
    },
    {
      "level": "H2",
      "text": "Note that similar proportions of those in the Exelon® and placebo groups are in",
      "page": 28
    },
    {
      "level": "H2",
      "text": "the intent-to-treat plus retrieved dropout groups used for the primary efficacy",
      "page": 28
    },
    {
      "level": "H2",
      "text": "analysis.",
      "page": 28
    },
    {
      "level": "H2",
      "text": "7.2.4 Demographic And Other Baseline Characteristics",
      "page": 28
    },
    {
      "level": "H2",
      "text": "As the sponsor table below indicates, baseline characteristics for age, gender,",
      "page": 28
    },
    {
      "level": "H2",
      "text": "and race were comparable between treatment groups. The table pertains to the",
      "page": 28
    },
    {
      "level": "H2",
      "text": "randomized/safety population",
      "page": 28
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 29
    },
    {
      "level": "H2",
      "text": "Baseline Parkinson’s Disease and dementia characteristics were also broadly",
      "page": 29
    },
    {
      "level": "H2",
      "text": "comparable between treatment groups, including entry Mini-Mental Status",
      "page": 29
    },
    {
      "level": "H2",
      "text": "Examination scores; the table depicts the randomized/safety population.",
      "page": 29
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 30
    },
    {
      "level": "H2",
      "text": "7.2.5 Study Medication",
      "page": 30
    },
    {
      "level": "H2",
      "text": "The cumulative duration of patient exposure is summarized by treatment group in",
      "page": 30
    },
    {
      "level": "H2",
      "text": "the next table, which I have copied from the submission. As might be expected",
      "page": 30
    },
    {
      "level": "H2",
      "text": "from the discontinuation rates in each treatment group alluded to before, the",
      "page": 30
    },
    {
      "level": "H2",
      "text": "mean duration of exposure was slightly lower in the Exelon® group than in the",
      "page": 30
    },
    {
      "level": "H2",
      "text": "placebo group.",
      "page": 30
    },
    {
      "level": "H2",
      "text": "The average daily Exelon® dose per treatment interval is in the next table, which",
      "page": 30
    },
    {
      "level": "H2",
      "text": "I have copied from the submission. The average daily Exelon® dose for the",
      "page": 30
    },
    {
      "level": "H2",
      "text": "entire study (± standard deviation) is 6.3 mg (± 2.3 mg).",
      "page": 30
    },
    {
      "level": "H1",
      "text": "7.2.6 Concomitant  (And Prior) Medication",
      "page": 30
    },
    {
      "level": "H2",
      "text": "Non-central nervous system related concomitant medications, taken both prior to",
      "page": 30
    },
    {
      "level": "H2",
      "text": "and after the start of the study, were used by 80.7% of patients in the Exelon®",
      "page": 30
    },
    {
      "level": "H2",
      "text": "group and 79.3% of patients in the placebo group. The most frequently reported",
      "page": 30
    },
    {
      "level": "H2",
      "text": "medication was aspirin (16.3% of Exelon®-treated patients and 19.6% of",
      "page": 30
    },
    {
      "level": "H2",
      "text": "placebo-treated patients).",
      "page": 30
    },
    {
      "level": "H2",
      "text": "Central nervous system-related concomitant medication taken within 4 weeks",
      "page": 30
    },
    {
      "level": "H2",
      "text": "prior to start of the study were used by 100% of those in the Exelon® group and",
      "page": 30
    },
    {
      "level": "H2",
      "text": "99.4% of those in the placebo group as might have been expected for a",
      "page": 30
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 31
    },
    {
      "level": "H2",
      "text": "population with Parkinson’s Disease. Concomitant medications that were central",
      "page": 31
    },
    {
      "level": "H2",
      "text": "nervous system-related were used by 100% of patients in both treatment groups.",
      "page": 31
    },
    {
      "level": "H2",
      "text": "The most widely used central-nervous system related concomitant medications",
      "page": 31
    },
    {
      "level": "H2",
      "text": "were those in the dopaminergic class. The pattern of dopaminergic agent use in",
      "page": 31
    },
    {
      "level": "H2",
      "text": "various classes is summarized in the following table, taken from the submission.",
      "page": 31
    },
    {
      "level": "H1",
      "text": "7.2.7 Efficacy Results",
      "page": 31
    },
    {
      "level": "H2",
      "text": "7.2.7.1 Primary Efficacy Results",
      "page": 31
    },
    {
      "level": "H2",
      "text": "7.2.7.1.1 ADAS-Cog",
      "page": 31
    },
    {
      "level": "H2",
      "text": "In the protocol-specified primary efficacy analysis of the ADAS-Cog (intent-to-",
      "page": 31
    },
    {
      "level": "H2",
      "text": "treat plus retrieved dropouts), the Exelon® treatment group improved by a mean",
      "page": 31
    },
    {
      "level": "H2",
      "text": "of 2.1 points, whereas the placebo group deteriorated by a mean of 0.7 points,",
      "page": 31
    },
    {
      "level": "H2",
      "text": "both at Week 24, with the difference being statistically significant as displayed in",
      "page": 31
    },
    {
      "level": "H2",
      "text": "the following table",
      "page": 31
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 32
    },
    {
      "level": "H2",
      "text": "Somewhat greater treatment differences, which were again nominally statistically",
      "page": 32
    },
    {
      "level": "H2",
      "text": "significant, were seen for both the intent-to-treat last-observation-carried-forward",
      "page": 32
    },
    {
      "level": "H2",
      "text": "and observed cases populations.",
      "page": 32
    },
    {
      "level": "H2",
      "text": "The time-course of the change in ADAS-Cog score in the intent-to-treat plus",
      "page": 32
    },
    {
      "level": "H2",
      "text": "retrieved dropouts  population in this study is displayed in the next figure, which I",
      "page": 32
    },
    {
      "level": "H2",
      "text": "have copied from the published report of this study.",
      "page": 32
    },
    {
      "level": "H2",
      "text": "A categorical analysis of the ADAS-Cog based on the proportion of patients",
      "page": 32
    },
    {
      "level": "H2",
      "text": "improving (i.e., improving by at least 4 points) in each treatment group at Weeks",
      "page": 32
    },
    {
      "level": "H2",
      "text": "16 and 24 is summarized in the following sponsor table.",
      "page": 32
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 33
    },
    {
      "level": "H2",
      "text": "For the categorical analysis above, nominally statistically significant treatment",
      "page": 33
    },
    {
      "level": "H2",
      "text": "differences were seen, as indicated by the table for the both the intent-to-treat",
      "page": 33
    },
    {
      "level": "H2",
      "text": "last-observation-carried-forward and observed cases populations.",
      "page": 33
    },
    {
      "level": "H2",
      "text": "7.2.7.1.2 ADCS-CGIC",
      "page": 33
    },
    {
      "level": "H2",
      "text": "In the protocol-specified primary efficacy analysis of the ADCS-CGIC (intent-to-",
      "page": 33
    },
    {
      "level": "H2",
      "text": "treat plus retrieved dropouts), the Exelon® treatment group showed a mean",
      "page": 33
    },
    {
      "level": "H2",
      "text": "score of 3.8 at Week 24, whereas the placebo group showed a mean score of",
      "page": 33
    },
    {
      "level": "H2",
      "text": "4.3 at the same time timepoint, with the difference being statistically significant as",
      "page": 33
    },
    {
      "level": "H2",
      "text": "displayed in the following sponsor table.",
      "page": 33
    },
    {
      "level": "H2",
      "text": "The categorical data for the intent-to-treat plus retrieved dropouts population in",
      "page": 33
    },
    {
      "level": "H2",
      "text": "the above table are also displayed in the following figure which I have copied",
      "page": 33
    },
    {
      "level": "H2",
      "text": "from the published report of this study.",
      "page": 33
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 34
    },
    {
      "level": "H2",
      "text": "Similar treatment differences, which were nominally statistically significant, were",
      "page": 34
    },
    {
      "level": "H2",
      "text": "seen for both the intent-to-treat last-observation-carried-forward and observed",
      "page": 34
    },
    {
      "level": "H2",
      "text": "cases populations.",
      "page": 34
    },
    {
      "level": "H2",
      "text": "The categorical analysis of the ADCS-CGIC in the next sponsor table indicates",
      "page": 34
    },
    {
      "level": "H2",
      "text": "that there were nominally statistically significantly higher proportions of patients",
      "page": 34
    },
    {
      "level": "H2",
      "text": "improving in the Exelon® group relative to the placebo group in all populations",
      "page": 34
    },
    {
      "level": "H2",
      "text": "analyzed.",
      "page": 34
    },
    {
      "level": "H2",
      "text": "7.2.7.2 Secondary Efficacy Results",
      "page": 34
    },
    {
      "level": "H2",
      "text": "7.2.7.2.1 ADCS-ADL",
      "page": 34
    },
    {
      "level": "H2",
      "text": "Nominal statistically significant treatment differences favoring Exelon® over",
      "page": 34
    },
    {
      "level": "H2",
      "text": "placebo were seen at Week 24 for the mean change from baseline to endpoint in",
      "page": 34
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 35
    },
    {
      "level": "H2",
      "text": "the ADCS-ADL in all 3 populations analyzed, including the intent-to-treat",
      "page": 35
    },
    {
      "level": "H2",
      "text": "retrieved dropout population. These results are in the sponsor table below.",
      "page": 35
    },
    {
      "level": "H2",
      "text": "7.2.7.2.2 Neuropsychiatry Inventory",
      "page": 35
    },
    {
      "level": "H2",
      "text": "Nominal statistically significant treatment differences favoring Exelon® over",
      "page": 35
    },
    {
      "level": "H2",
      "text": "placebo were seen at Week 24 for the mean change from baseline to endpoint in",
      "page": 35
    },
    {
      "level": "H2",
      "text": "the 10-point Neuropsychiatry Inventory total score in the intent-to-treat retrieved",
      "page": 35
    },
    {
      "level": "H2",
      "text": "dropout and intent-to-treat last-observation-carried-forward populations (these",
      "page": 35
    },
    {
      "level": "H2",
      "text": "results are displayed in the table below).",
      "page": 35
    },
    {
      "level": "H2",
      "text": "The proportion of patients with an improved 10-point Neuropsychiatry Inventory",
      "page": 35
    },
    {
      "level": "H2",
      "text": "total score was also reported to show a nominally statistically significant",
      "page": 35
    },
    {
      "level": "H2",
      "text": "superiority to placebo in all 3 analysis populations. Treatment group differences",
      "page": 35
    },
    {
      "level": "H2",
      "text": "on the 12- point Neuropsychiatry Inventory were not even nominally statistically",
      "page": 35
    },
    {
      "level": "H2",
      "text": "significant.",
      "page": 35
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 36
    },
    {
      "level": "H2",
      "text": "A nominally statistically significant treatment difference favoring Exelon® was",
      "page": 36
    },
    {
      "level": "H2",
      "text": "seen for the Neuropsychiatry Inventory Caregiver Distress score for a single",
      "page": 36
    },
    {
      "level": "H2",
      "text": "item: aberrant motor behavior.",
      "page": 36
    },
    {
      "level": "H2",
      "text": "7.2.7.2.3 Health Economic Parameters",
      "page": 36
    },
    {
      "level": "H2",
      "text": "The analysis of these measures is to be reported separately.",
      "page": 36
    },
    {
      "level": "H2",
      "text": "7.2.7.2.4 Cognitive Drug Research – Attention Battery",
      "page": 36
    },
    {
      "level": "H2",
      "text": "The combined Power of Attention mean change from baseline score at Week 24",
      "page": 36
    },
    {
      "level": "H2",
      "text": "showed a nominally statistically significant difference from placebo.",
      "page": 36
    },
    {
      "level": "H2",
      "text": "7.2.7.2.5 Executive Functioning Tests",
      "page": 36
    },
    {
      "level": "H2",
      "text": "Since D-KEFS executive function tests were not performed at all centers, the",
      "page": 36
    },
    {
      "level": "H2",
      "text": "analyses were performed only in the Observed Cases population.",
      "page": 36
    },
    {
      "level": "H2",
      "text": "On the D-KEFS Letter Fluency test change score, a nominally statistically",
      "page": 36
    },
    {
      "level": "H2",
      "text": "significant treatment difference was seen at Week 24, with the Exelon® group",
      "page": 36
    },
    {
      "level": "H2",
      "text": "improving and placebo group deteriorating on mean scores (see sponsor table",
      "page": 36
    },
    {
      "level": "H2",
      "text": "below).",
      "page": 36
    },
    {
      "level": "H2",
      "text": "In the D-KEFS Color Word Interference and Card Sorting Tests, a few sub-",
      "page": 36
    },
    {
      "level": "H2",
      "text": "scores showed nominally statistically significant differences favoring Exelon®.",
      "page": 36
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 37
    },
    {
      "level": "H2",
      "text": "On the Symbol Digits Modality Test, the number of correct substitutions showed",
      "page": 37
    },
    {
      "level": "H2",
      "text": "a nominally statistically significant improvement in favor of Exelon® at Week 24.",
      "page": 37
    },
    {
      "level": "H2",
      "text": "7.2.7.2.6 Ten Point Clock Test",
      "page": 37
    },
    {
      "level": "H2",
      "text": "This test too was performed only on a subset of the study population and",
      "page": 37
    },
    {
      "level": "H2",
      "text": "analyses were confined to the Observed Cases dataset. As the sponsor-supplied",
      "page": 37
    },
    {
      "level": "H2",
      "text": "table below indicates, the mean change from baseline score for this small subset",
      "page": 37
    },
    {
      "level": "H2",
      "text": "improved slightly in the Exelon® group and deteriorated slightly in the placebo",
      "page": 37
    },
    {
      "level": "H2",
      "text": "group, with the difference being nominally statistically significant.",
      "page": 37
    },
    {
      "level": "H2",
      "text": "7.2.7.2.7 Mini-Mental Status Examination",
      "page": 37
    },
    {
      "level": "H2",
      "text": "In the intent-to-treat plus retrieved dropouts population, mean Mini-Mental Status",
      "page": 37
    },
    {
      "level": "H2",
      "text": "Examination scores increased by 0.8 points in the Exelon® group and decreased",
      "page": 37
    },
    {
      "level": "H2",
      "text": "by 0.2 points in the placebo, at Week 24, with the difference being nominally",
      "page": 37
    },
    {
      "level": "H2",
      "text": "statistically significant. Similar results were seen with the other two analysis",
      "page": 37
    },
    {
      "level": "H2",
      "text": "populations.",
      "page": 37
    },
    {
      "level": "H2",
      "text": "7.2.7.3 Overall Efficacy Response",
      "page": 37
    },
    {
      "level": "H2",
      "text": "An overall responder was defined as a patient with a combination of the following",
      "page": 37
    },
    {
      "level": "H2",
      "text": "The categorical analysis of the percentage of overall responders showed a",
      "page": 37
    },
    {
      "level": "H2",
      "text": "nominally statistically significant treatment difference favoring Exelon® over",
      "page": 37
    },
    {
      "level": "H2",
      "text": "placebo at Week 24 for the intent-to-treat-last-observation-carried-forward",
      "page": 37
    },
    {
      "level": "H2",
      "text": "population only (20% of patients in the Exelon® group and 13% of patients in the",
      "page": 37
    },
    {
      "level": "H2",
      "text": "placebo group were considered responders in this dataset).",
      "page": 37
    },
    {
      "level": "H2",
      "text": "7.2.7.4 Pharmacogenetic Analyses",
      "page": 37
    },
    {
      "level": "H2",
      "text": "302 out of 541 randomized patients consented to pharmacogenetic sampling.",
      "page": 37
    },
    {
      "level": "H2",
      "text": "The results of these analyses are to be reported separately.",
      "page": 37
    },
    {
      "level": "H2",
      "text": "7.2.7.5 Biomarker Analyses",
      "page": 37
    },
    {
      "level": "H2",
      "text": "356 and 324 patients consent to biomarker serum and urine sampling,",
      "page": 37
    },
    {
      "level": "H2",
      "text": "respectively. The results of these analyses are to be reported separately.",
      "page": 37
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 38
    },
    {
      "level": "H1",
      "text": "7.2.8 Safety Results",
      "page": 38
    },
    {
      "level": "H2",
      "text": "7.2.8.1 Overall Adverse Event Experience",
      "page": 38
    },
    {
      "level": "H2",
      "text": "The overall incidence of all adverse events (i.e., proportion of patients",
      "page": 38
    },
    {
      "level": "H2",
      "text": "randomized who had any adverse event) was higher in the Exelon® group",
      "page": 38
    },
    {
      "level": "H2",
      "text": "(83.7%) than in the placebo group (70.9%).",
      "page": 38
    },
    {
      "level": "H2",
      "text": "The following table, copied from the submission, summarizes the incidence of the",
      "page": 38
    },
    {
      "level": "H2",
      "text": "most common adverse events (those with an incidence of at least 5% in either",
      "page": 38
    },
    {
      "level": "H2",
      "text": "treatment group) in this study, in descending order of frequency.",
      "page": 38
    },
    {
      "level": "H2",
      "text": "As the table above indicates, the most common of the adverse events, all of",
      "page": 38
    },
    {
      "level": "H2",
      "text": "which were more frequent in the Exelon® group than in the placebo group, were",
      "page": 38
    },
    {
      "level": "H2",
      "text": "nausea, vomiting, tremor, diarrhea, and anorexia. The incidence of dizziness was",
      "page": 38
    },
    {
      "level": "H2",
      "text": "also substantially greater in the Exelon® group than in the placebo group.",
      "page": 38
    },
    {
      "level": "H2",
      "text": "The next table, also copied from the submission, indicates the overall incidence",
      "page": 38
    },
    {
      "level": "H2",
      "text": "of adverse events during each (4-week) treatment period.",
      "page": 38
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 39
    },
    {
      "level": "H2",
      "text": "As the table above indicates, these events appear to have been more frequent,",
      "page": 39
    },
    {
      "level": "H2",
      "text": "in the Exelon® group, during the titration phase of this study than during the",
      "page": 39
    },
    {
      "level": "H2",
      "text": "maintenance phase.",
      "page": 39
    },
    {
      "level": "H2",
      "text": "7.2.8.2 Deaths, Serious Adverse Events, And Discontinuations Due To Adverse Events",
      "page": 39
    },
    {
      "level": "H2",
      "text": "The incidence of adverse events in each item in this grouping is summarized in",
      "page": 39
    },
    {
      "level": "H2",
      "text": "the following table, which I have copied from the submission.",
      "page": 39
    },
    {
      "level": "H2",
      "text": "7.2.8.2.1 Deaths",
      "page": 39
    },
    {
      "level": "H2",
      "text": "4 patients (1.1% of those randomized) in the Exelon® group and 7 patients in the",
      "page": 39
    },
    {
      "level": "H2",
      "text": "placebo group (3.9% of those randomized) died during the study. All deaths",
      "page": 39
    },
    {
      "level": "H2",
      "text": "listed occurred while receiving study drug or within 15 days of study drug",
      "page": 39
    },
    {
      "level": "H2",
      "text": "discontinuation (all deaths that occurred while on study drug or within 30 days of",
      "page": 39
    },
    {
      "level": "H2",
      "text": "study drug discontinuation were to be captured).",
      "page": 39
    },
    {
      "level": "H2",
      "text": "Individual deaths in both the Exelon® and placebo groups are listed in the",
      "page": 39
    },
    {
      "level": "H2",
      "text": "following table, which I have copied from the submission.",
      "page": 39
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 40
    },
    {
      "level": "H2",
      "text": "7.2.8.2.2 Non-Fatal Serious Adverse Events",
      "page": 40
    },
    {
      "level": "H2",
      "text": "13.0% of those in the Exelon® group and 14.5% of those in the placebo group",
      "page": 40
    },
    {
      "level": "H2",
      "text": "experienced a non-fatal serious adverse event during this study. The incidence of",
      "page": 40
    },
    {
      "level": "H2",
      "text": "such events by system organ class is in the following table.",
      "page": 40
    },
    {
      "level": "H2",
      "text": "I have read the listings for all individual serious adverse events. It is hard to link",
      "page": 40
    },
    {
      "level": "H2",
      "text": "the individual events that occurred in patients treated with Exelon® to the drug.",
      "page": 40
    },
    {
      "level": "H2",
      "text": "All events appeared to be consistent with intercurrent illnesses common in the",
      "page": 40
    },
    {
      "level": "H2",
      "text": "elderly, and their complications.",
      "page": 40
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 41
    },
    {
      "level": "H2",
      "text": "7.2.8.2.3 Discontinuations Due To Adverse Events",
      "page": 41
    },
    {
      "level": "H2",
      "text": "66 patients (18.2%) receiving Exelon® and 20 patients (11.2%) of those",
      "page": 41
    },
    {
      "level": "H2",
      "text": "receiving placebo discontinued study drug prematurely on account of an adverse",
      "page": 41
    },
    {
      "level": "H2",
      "text": "event.",
      "page": 41
    },
    {
      "level": "H2",
      "text": "Individual adverse events leading to discontinuation that occurred in at least 2",
      "page": 41
    },
    {
      "level": "H2",
      "text": "Exelon®-treated patients are in the following table which I have created from one",
      "page": 41
    },
    {
      "level": "H2",
      "text": "supplied by the sponsor.",
      "page": 41
    },
    {
      "level": "H3",
      "text": "Nausea",
      "page": 41
    },
    {
      "level": "H2",
      "text": "I have read the listings for all individual adverse events that led to treatment",
      "page": 41
    },
    {
      "level": "H2",
      "text": "discontinuation. With the exception of events such as nausea, vomiting, and",
      "page": 41
    },
    {
      "level": "H2",
      "text": "diarrhea, which could be a consequence of the cholinomimetic effects of",
      "page": 41
    },
    {
      "level": "H2",
      "text": "Exelon®, it is hard to link the individual events that occurred in patients treated",
      "page": 41
    },
    {
      "level": "H2",
      "text": "with Exelon® to the drug. All other events appeared to be consistent with",
      "page": 41
    },
    {
      "level": "H2",
      "text": "intercurrent illnesses common in the elderly (and in the study population) and",
      "page": 41
    },
    {
      "level": "H2",
      "text": "their complications.",
      "page": 41
    },
    {
      "level": "H2",
      "text": "7.2.8.3 Other Significant Adverse Events",
      "page": 41
    },
    {
      "level": "H2",
      "text": "Adverse event terms that might be considered to possibly represent a worsening",
      "page": 41
    },
    {
      "level": "H2",
      "text": "of Parkinson’s Disease were pre-specified in the study protocol. The incidence of",
      "page": 41
    },
    {
      "level": "H2",
      "text": "all such events was higher in the Exelon® group (27.3%) than in the placebo",
      "page": 41
    },
    {
      "level": "H2",
      "text": "group (15.6%). The incidence of individual adverse events is summarized in the",
      "page": 41
    },
    {
      "level": "H2",
      "text": "following table.  [A number of additional event terms did not occur at all].",
      "page": 41
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 42
    },
    {
      "level": "H2",
      "text": "A higher incidence of tremor, worsening of Parkinson’s Disease, worsening of",
      "page": 42
    },
    {
      "level": "H2",
      "text": "parkinsonism, bradykinesia, dyskinesia, abnormal gait, and salivary",
      "page": 42
    },
    {
      "level": "H2",
      "text": "hypersecretion in the Exelon® group is noteworthy.",
      "page": 42
    },
    {
      "level": "H2",
      "text": "7.2.8.4 Laboratory Tests",
      "page": 42
    },
    {
      "level": "H2",
      "text": "The sponsor has highlighted changes from baseline in serum amylase, lipase,",
      "page": 42
    },
    {
      "level": "H2",
      "text": "and prolactin, which were more apparent in the Exelon® group than in the",
      "page": 42
    },
    {
      "level": "H2",
      "text": "placebo.",
      "page": 42
    },
    {
      "level": "H2",
      "text": "As the sponsor table below indicates, the mean change from baseline in these",
      "page": 42
    },
    {
      "level": "H2",
      "text": "parameters was greater in the Exelon® group than in the placebo group. The",
      "page": 42
    },
    {
      "level": "H2",
      "text": "table also shows the mean levels for each parameter at Week 24.",
      "page": 42
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 43
    },
    {
      "level": "H2",
      "text": "The proportions of patients in each treatment group who had normal serum",
      "page": 43
    },
    {
      "level": "H2",
      "text": "amylase, lipase, and prolactin levels at baseline, but higher than normal values at",
      "page": 43
    },
    {
      "level": "H2",
      "text": "Week 24 are in the following table. Again, the proportion of such elevations is",
      "page": 43
    },
    {
      "level": "H2",
      "text": "higher in the Exelon® group than in the placebo group.",
      "page": 43
    },
    {
      "level": "H2",
      "text": "Narratives have been provided for all patients with elevated serum amylase",
      "page": 43
    },
    {
      "level": "H2",
      "text": "and/or lipase during the study.",
      "page": 43
    },
    {
      "level": "H2",
      "text": "The sponsor also points out the following:",
      "page": 43
    },
    {
      "level": "H2",
      "text": "The incidence of other newly occurring notable laboratory abnormalities is in the",
      "page": 43
    },
    {
      "level": "H2",
      "text": "following table which I have copied from the submission:",
      "page": 43
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 44
    },
    {
      "level": "H2",
      "text": "7.2.8.5 Vital Signs",
      "page": 44
    },
    {
      "level": "H2",
      "text": "The number of patients with newly occurring or worsening vital sign and weight",
      "page": 44
    },
    {
      "level": "H2",
      "text": "abnormalities was comparable between treatment groups, as indicated in the",
      "page": 44
    },
    {
      "level": "H2",
      "text": "following sponsor table.",
      "page": 44
    },
    {
      "level": "H2",
      "text": "The mean changes from baseline in these parameters were comparable in the 2",
      "page": 44
    },
    {
      "level": "H2",
      "text": "treatment groups.",
      "page": 44
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 45
    },
    {
      "level": "H2",
      "text": "7.2.8.6 Electrocardiograms",
      "page": 45
    },
    {
      "level": "H2",
      "text": "Summary statistics for electrocardiogram parameters have been reviewed fully.",
      "page": 45
    },
    {
      "level": "H2",
      "text": "The sponsor has drawn attention to the following:",
      "page": 45
    },
    {
      "level": "H2",
      "text": "7.2.8.7 UPDRS Part III Scores",
      "page": 45
    },
    {
      "level": "H2",
      "text": "The UPDRS motor scores were used as a means of assessing changes in the",
      "page": 45
    },
    {
      "level": "H2",
      "text": "motor manifestations of Parkinson’s Disease during the study. The mean change",
      "page": 45
    },
    {
      "level": "H2",
      "text": "from baseline scores at Weeks 16 and 24 are summarized in the following table,",
      "page": 45
    },
    {
      "level": "H2",
      "text": "which I have copied from the submission.",
      "page": 45
    },
    {
      "level": "H2",
      "text": "The changes in each treatment group at each timepoint were similar and were",
      "page": 45
    },
    {
      "level": "H2",
      "text": "not considered clinically significant. The differences in change score were not",
      "page": 45
    },
    {
      "level": "H2",
      "text": "even nominally statistically significant.",
      "page": 45
    },
    {
      "level": "H2",
      "text": "The sponsor also points out that statistically significant treatment differences",
      "page": 45
    },
    {
      "level": "H2",
      "text": "were not seen for any of the individual UPDRS Part III item scores. The mean",
      "page": 45
    },
    {
      "level": "H2",
      "text": "change from baseline for the tremor score at Week 24 was 0.1 ± 2.6 for the",
      "page": 45
    },
    {
      "level": "H2",
      "text": "Exelon® group and 0.0 ± 2.1 in the placebo group.",
      "page": 45
    },
    {
      "level": "H1",
      "text": "7.3 Sponsor’s Conclusions",
      "page": 45
    },
    {
      "level": "H2",
      "text": "In this trial, which was conducted in dementia associated with Parkinson’s",
      "page": 45
    },
    {
      "level": "H2",
      "text": "Disease, the efficacy of Exelon® in a dose of 3 to 12 mg/day for 24 weeks was",
      "page": 45
    },
    {
      "level": "H2",
      "text": "significantly superior to that of placebo on a measure of cognition (which was",
      "page": 45
    },
    {
      "level": "H2",
      "text": "assessed by the ADAS-Cog) and on a measure of the clinical global rating of",
      "page": 45
    },
    {
      "level": "H2",
      "text": "change (ADCS-CGIC). The primary objective of the study was therefore",
      "page": 45
    },
    {
      "level": "H2",
      "text": "achieved",
      "page": 45
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 46
    },
    {
      "level": "H2",
      "text": "Secondary efficacy measures that assessed activities of daily living, behavior,",
      "page": 46
    },
    {
      "level": "H2",
      "text": "attention and executive functioning also improved more significantly in those",
      "page": 46
    },
    {
      "level": "H2",
      "text": "treated with Exelon® than in those treated with placebo.",
      "page": 46
    },
    {
      "level": "H2",
      "text": "The safety profile of Exelon® in this study was consistent with published data for",
      "page": 46
    },
    {
      "level": "H2",
      "text": "Exelon® administered to patients with Alzheimer’s Disease. While the incidence",
      "page": 46
    },
    {
      "level": "H2",
      "text": "of adverse events associated with a worsening of Parkinson’s Disease was",
      "page": 46
    },
    {
      "level": "H2",
      "text": "higher in the Exelon® group than in the placebo group, the UPDRS Part III",
      "page": 46
    },
    {
      "level": "H2",
      "text": "(motor) ratings did not reveal any clinically or statistically relevant difference",
      "page": 46
    },
    {
      "level": "H2",
      "text": "between treatment groups for either the total score or any of the individual item",
      "page": 46
    },
    {
      "level": "H2",
      "text": "scores. Changes in laboratory tests and electrocardiograms were considered",
      "page": 46
    },
    {
      "level": "H2",
      "text": "clinically insignificant.",
      "page": 46
    },
    {
      "level": "H1",
      "text": "7.4 Study Abstract",
      "page": 46
    },
    {
      "level": "H2",
      "text": "Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van",
      "page": 46
    },
    {
      "level": "H2",
      "text": "Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R.",
      "page": 46
    },
    {
      "level": "H2",
      "text": "Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509-18",
      "page": 46
    },
    {
      "level": "H2",
      "text": "BACKGROUND: Cholinergic deficits are prominent in patients who have dementia associated with",
      "page": 46
    },
    {
      "level": "H2",
      "text": "Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such",
      "page": 46
    },
    {
      "level": "H2",
      "text": "patients.",
      "page": 46
    },
    {
      "level": "H2",
      "text": "METHODS: Patients in whom mild-to-moderate dementia developed at least 2 years after they received a",
      "page": 46
    },
    {
      "level": "H2",
      "text": "clinical diagnosis of Parkinson's disease were randomly assigned to receive placebo or 3 to 12 mg of",
      "page": 46
    },
    {
      "level": "H2",
      "text": "rivastigmine per day for 24 weeks. Primary efficacy variables were the scores for the cognitive subscale of",
      "page": 46
    },
    {
      "level": "H2",
      "text": "the Alzheimer's Disease Assessment Scale (ADAS-cog) and Alzheimer's Disease Cooperative Study-",
      "page": 46
    },
    {
      "level": "H2",
      "text": "Clinician's Global Impression of Change (ADCS-CGIC). Secondary clinical outcomes were the scores for",
      "page": 46
    },
    {
      "level": "H2",
      "text": "the Alzheimer's Disease Cooperative Study-Activities of Daily Living, the 10-item Neuropsychiatric",
      "page": 46
    },
    {
      "level": "H2",
      "text": "Inventory, the Mini-Mental State Examination, Cognitive Drug Research power of attention tests, the Verbal",
      "page": 46
    },
    {
      "level": "H2",
      "text": "Fluency test, and the Ten Point Clock-Drawing test.",
      "page": 46
    },
    {
      "level": "H2",
      "text": "RESULTS: A total of 541 patients were enrolled, and 410 completed the study. The outcomes were better",
      "page": 46
    },
    {
      "level": "H2",
      "text": "among patients treated with rivastigmine than among those who received placebo; however, the differences",
      "page": 46
    },
    {
      "level": "H2",
      "text": "between these two groups were moderate and similar to those reported in trials of rivastigmine for",
      "page": 46
    },
    {
      "level": "H2",
      "text": "Alzheimer's disease. Rivastigmine-treated patients had a mean improvement of 2.1 points in the score for",
      "page": 46
    },
    {
      "level": "H2",
      "text": "the 70-point ADAS-cog, from a baseline score of 23.8, as compared with a 0.7-point worsening in the",
      "page": 46
    },
    {
      "level": "H2",
      "text": "placebo group, from a baseline score of 24.3 (P<0.001). Clinically meaningful improvements in the scores",
      "page": 46
    },
    {
      "level": "H2",
      "text": "for the ADCS-CGIC were observed in 19.8 percent of patients in the rivastigmine group and 14.5 percent of",
      "page": 46
    },
    {
      "level": "H2",
      "text": "those in the placebo group, and clinically meaningful worsening was observed in 13.0 percent and 23.1",
      "page": 46
    },
    {
      "level": "H2",
      "text": "percent, respectively (mean score at 24 weeks, 3.8 and 4.3, respectively; P=0.007). Significantly better",
      "page": 46
    },
    {
      "level": "H2",
      "text": "outcomes were seen with rivastigmine with respect to all secondary efficacy variables. The most frequent",
      "page": 46
    },
    {
      "level": "H2",
      "text": "adverse events were nausea (affecting 29.0 percent of patients in the rivastigmine group and 11.2 percent",
      "page": 46
    },
    {
      "level": "H2",
      "text": "of those in the placebo group, P<0.001), vomiting (16.6 and 1.7 percent, P<0.001), and tremor (10.2 and 3.9",
      "page": 46
    },
    {
      "level": "H2",
      "text": "percent, P=0.01).",
      "page": 46
    },
    {
      "level": "H2",
      "text": "CONCLUSIONS: In this placebo-controlled study, rivastigmine was associated with moderate improvements",
      "page": 46
    },
    {
      "level": "H2",
      "text": "in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor.",
      "page": 46
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 47
    },
    {
      "level": "H1",
      "text": "7.5 Additional Observations And Comments By Agency Statistical",
      "page": 47
    },
    {
      "level": "H1",
      "text": "Reviewer About Study 2311",
      "page": 47
    },
    {
      "level": "H2",
      "text": "The Agency Biometrics Reviewer for this submission, Dr Joanne Zhang, has",
      "page": 47
    },
    {
      "level": "H2",
      "text": "made the following main observations, and drawn the overall conclusions",
      "page": 47
    },
    {
      "level": "H2",
      "text": "outlined below regarding the efficacy results of this study",
      "page": 47
    },
    {
      "level": "H2",
      "text": "7.5.1  Observations",
      "page": 47
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 48
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 49
    },
    {
      "level": "H2",
      "text": "7.5.2 Conclusions",
      "page": 49
    },
    {
      "level": "H2",
      "text": "Dr Zhang has concluded that the data provided support the efficacy of Exelon®",
      "page": 49
    },
    {
      "level": "H2",
      "text": "in Parkinson’s Disease Dementia, based on the prospectively-specified statistical",
      "page": 49
    },
    {
      "level": "H2",
      "text": "analysis plan; several sensitivity analyses support this conclusion. She does,",
      "page": 49
    },
    {
      "level": "H2",
      "text": "however, note that a gender-based subgroup analysis suggests that this benefit",
      "page": 49
    },
    {
      "level": "H2",
      "text": "may not extend to women.",
      "page": 49
    },
    {
      "level": "H1",
      "text": "7.6 Reviewer’s Comments",
      "page": 49
    },
    {
      "level": "H2",
      "text": "7.6.1 Efficacy Of Exelon®",
      "page": 49
    },
    {
      "level": "H2",
      "text": "This study does indicate that Exelon® in a dose of 3 to 12 mg/day did have",
      "page": 49
    },
    {
      "level": "H2",
      "text": "efficacy in the entire study population, based on prospectively-specified criteria.",
      "page": 49
    },
    {
      "level": "H2",
      "text": "Although a statistically significant treatment effect was not seen in women alone",
      "page": 49
    },
    {
      "level": "H2",
      "text": "on the gender-based subgroup analysis for the ADCS-CGIC performed by the",
      "page": 49
    },
    {
      "level": "H2",
      "text": "Agency Biometrics Reviewer, the effect sizes (and variance) in that subgroup for",
      "page": 49
    },
    {
      "level": "H2",
      "text": "the mean change from baseline to Week 24 in ADAS-Cog score and mean",
      "page": 49
    },
    {
      "level": "H2",
      "text": "ADCS-CGIC score were similar to those seen in men, while fewer women than",
      "page": 49
    },
    {
      "level": "H2",
      "text": "men were enrolled in the study.",
      "page": 49
    },
    {
      "level": "H2",
      "text": "The implications of the results of this study in the context of the new claim (i.e.,",
      "page": 49
    },
    {
      "level": "H2",
      "text": "“treatment of mild to moderate dementia associated with Parkinson’s Disease”)",
      "page": 49
    },
    {
      "level": "H2",
      "text": "sought by the sponsor in this Supplemental Application are discussed later in the",
      "page": 49
    },
    {
      "level": "H2",
      "text": "review.",
      "page": 49
    },
    {
      "level": "H2",
      "text": "7.6.2 Safety Of Exelon®",
      "page": 49
    },
    {
      "level": "H2",
      "text": "The safety data for this study indicate that the adverse event profile of Exelon® in",
      "page": 49
    },
    {
      "level": "H2",
      "text": "the study population was largely similar to that seen in clinical trials with",
      "page": 49
    },
    {
      "level": "H2",
      "text": "Alzheimer’s Disease, in that there was a distinctly higher frequency of nausea,",
      "page": 49
    },
    {
      "level": "H2",
      "text": "vomiting, diarrhea, and anorexia in those exposed to Exelon® than in those",
      "page": 49
    },
    {
      "level": "H2",
      "text": "exposed to placebo.",
      "page": 49
    },
    {
      "level": "H2",
      "text": "Of special relevance to a population with Parkinson’s Disease, was the",
      "page": 49
    },
    {
      "level": "H2",
      "text": "observation that tremor (which was not further characterized) was recorded as a",
      "page": 49
    },
    {
      "level": "H2",
      "text": "treatment-emergent adverse event in about 10% of those received Exelon® and",
      "page": 49
    },
    {
      "level": "H2",
      "text": "4% of those who received placebo in this study (in the controlled clinical trials of",
      "page": 49
    },
    {
      "level": "H2",
      "text": "Exelon® that were conducted prior to its approval for Alzheimer’s Disease,",
      "page": 49
    },
    {
      "level": "H2",
      "text": "tremor was seen in about 4% of  those who received Exelon® and 1% of those",
      "page": 49
    },
    {
      "level": "H2",
      "text": "who received placebo). Several other adverse events that may conceivably have",
      "page": 49
    },
    {
      "level": "H2",
      "text": "been linked to a worsening in Parkinson’s Disease were also more frequent in",
      "page": 49
    },
    {
      "level": "H2",
      "text": "those treated with Exelon® than in those treated with placebo, but their incidence",
      "page": 49
    },
    {
      "level": "H2",
      "text": "in the Exelon®-treated group was lower than that of tremor. However, changes in",
      "page": 49
    },
    {
      "level": "H2",
      "text": "UPDRS total motor scores, probably a more objective measure of change in the",
      "page": 49
    },
    {
      "level": "H2",
      "text": "motor manifestations of Parkinson’s Disease than the incidence of treatment-",
      "page": 49
    },
    {
      "level": "H2",
      "text": "emergent adverse events, showed no meaningful difference between treatment",
      "page": 49
    },
    {
      "level": "H2",
      "text": "groups.",
      "page": 49
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 50
    },
    {
      "level": "H1",
      "text": "8. Study 2311E1 (Open-Label Uncontrolled Extension To Study",
      "page": 50
    },
    {
      "level": "H1",
      "text": "2311)",
      "page": 50
    },
    {
      "level": "H2",
      "text": "The protocol and main safety results for this study will be summarized briefly",
      "page": 50
    },
    {
      "level": "H2",
      "text": "below. Note that I have not summarized the efficacy data for this study at all,",
      "page": 50
    },
    {
      "level": "H2",
      "text": "despite presentation of those data by the sponsor in the study report, as",
      "page": 50
    },
    {
      "level": "H2",
      "text": "uncontrolled data are not used to determine efficacy for regulatory purposes.",
      "page": 50
    },
    {
      "level": "H1",
      "text": "8.1 Protocol 2311E1",
      "page": 50
    },
    {
      "level": "H2",
      "text": "Only a brief outline of the protocol has been provided below.",
      "page": 50
    },
    {
      "level": "H2",
      "text": "8.1.1 Title",
      "page": 50
    },
    {
      "level": "H2",
      "text": "An Open-Label 24-Week Extension To A 24-Week, Prospective, Randomized,",
      "page": 50
    },
    {
      "level": "H2",
      "text": "Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The",
      "page": 50
    },
    {
      "level": "H2",
      "text": "Efficacy, Tolerability, And Safety Of Exelon® (Rivastigmine) Capsules In Patients",
      "page": 50
    },
    {
      "level": "H2",
      "text": "With Parkinson’s Disease Dementia",
      "page": 50
    },
    {
      "level": "H2",
      "text": "8.1.2 Objectives",
      "page": 50
    },
    {
      "level": "H2",
      "text": "8.1.2.1 Primary",
      "page": 50
    },
    {
      "level": "H2",
      "text": "To evaluate the safety and tolerability of open-label Exelon® (3 to 12 mg/day) for",
      "page": 50
    },
    {
      "level": "H2",
      "text": "up to 24 weeks in patients who previously completed Study 2311, and to provide",
      "page": 50
    },
    {
      "level": "H2",
      "text": "continued access to Exelon®",
      "page": 50
    },
    {
      "level": "H2",
      "text": "8.1.2.2 Secondary",
      "page": 50
    },
    {
      "level": "H2",
      "text": "To evaluate the effects of Exelon® on cognition, including executive function,",
      "page": 50
    },
    {
      "level": "H2",
      "text": "activities of daily living, behavioral symptoms and health economic parameters",
      "page": 50
    },
    {
      "level": "H2",
      "text": "including caregiver distress and caregiver burden",
      "page": 50
    },
    {
      "level": "H2",
      "text": "8.1.3 Design, Duration, Sample Size, Dosage",
      "page": 50
    },
    {
      "level": "H2",
      "text": "This was to be an open-label uncontrolled extension study.",
      "page": 50
    },
    {
      "level": "H2",
      "text": "540 patients were planned to be enrolled in the preceding double-blind study.",
      "page": 50
    },
    {
      "level": "H2",
      "text": "The design of this study and its predecessor are summarized in the following",
      "page": 50
    },
    {
      "level": "H2",
      "text": "table, which I have copied from the submission.",
      "page": 50
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 51
    },
    {
      "level": "H2",
      "text": "4 dose levels were to be used for Exelon® (and for matching placebo). The dose",
      "page": 51
    },
    {
      "level": "H2",
      "text": "levels for Exelon® are shown in the following table.",
      "page": 51
    },
    {
      "level": "H3",
      "text": "Dose Level",
      "page": 51
    },
    {
      "level": "H2",
      "text": "The actual dosing regime was to be as follows:",
      "page": 51
    },
    {
      "level": "H2",
      "text": "8.1.4 Key Inclusion Criteria",
      "page": 51
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 52
    },
    {
      "level": "H2",
      "text": "8.1.5 Study Schedule",
      "page": 52
    },
    {
      "level": "H2",
      "text": "The study schedule is summarized in the following table, which I have copied",
      "page": 52
    },
    {
      "level": "H2",
      "text": "from the submission.",
      "page": 52
    },
    {
      "level": "H1",
      "text": "8.1.6 Safety Outcome Measures",
      "page": 52
    },
    {
      "level": "H2",
      "text": "Adverse events, safety laboratory tests, vital signs, body weight,",
      "page": 52
    },
    {
      "level": "H2",
      "text": "electrocardiograms, and UPDRS Part III (Motor Function).",
      "page": 52
    },
    {
      "level": "H1",
      "text": "8.2 Safety Results Of Study 2311E1",
      "page": 52
    },
    {
      "level": "H2",
      "text": "8.2.1 Patient Disposition",
      "page": 52
    },
    {
      "level": "H2",
      "text": "433 patients enrolled in Study 2311 were eligible to be enrolled in Study 2311E1;",
      "page": 52
    },
    {
      "level": "H2",
      "text": "334 patients actually consented to participate in the latter study, which 273",
      "page": 52
    },
    {
      "level": "H2",
      "text": "patients completed.",
      "page": 52
    },
    {
      "level": "H2",
      "text": "Patient disposition is summarized in the following sponsor table, with patients",
      "page": 52
    },
    {
      "level": "H2",
      "text": "grouped according to whether they took Exelon® (“Exe”) or placebo (“Plc”) in the",
      "page": 52
    },
    {
      "level": "H2",
      "text": "preceding double-blind study. Note that all discontinuations as well as",
      "page": 52
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 53
    },
    {
      "level": "H2",
      "text": "discontinuations due to  adverse events were more common in those earlier",
      "page": 53
    },
    {
      "level": "H2",
      "text": "exposed to placebo than in those previously exposed to Exelon®.",
      "page": 53
    },
    {
      "level": "H1",
      "text": "8.2.2 Exposure To Study Drug",
      "page": 53
    },
    {
      "level": "H2",
      "text": "The mean duration of exposure to Exelon® in this study was 21.6 weeks, and",
      "page": 53
    },
    {
      "level": "H2",
      "text": "was similar in those exposed to Exelon® earlier as compared with those exposed",
      "page": 53
    },
    {
      "level": "H2",
      "text": "to placebo (see the sponsor table below).",
      "page": 53
    },
    {
      "level": "H1",
      "text": "8.2.3 Concomitant Medication",
      "page": 53
    },
    {
      "level": "H2",
      "text": "A slightly larger proportion of those who previously received Exelon® (than those",
      "page": 53
    },
    {
      "level": "H2",
      "text": "who earlier received placebo) initiated new dopaminergic therapy or increased",
      "page": 53
    },
    {
      "level": "H2",
      "text": "their dose of dopaminergic medication during the open-label extension phase, as",
      "page": 53
    },
    {
      "level": "H2",
      "text": "indicated by the table below, which I have copied from the submission.",
      "page": 53
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 54
    },
    {
      "level": "H1",
      "text": "8.2.4 Overall Adverse Event Experience",
      "page": 54
    },
    {
      "level": "H2",
      "text": "75.4% of patients enrolled in this  study experienced adverse events with the",
      "page": 54
    },
    {
      "level": "H2",
      "text": "incidence being comparable across the 2 pre-treatment groups. However,",
      "page": 54
    },
    {
      "level": "H2",
      "text": "gastrointestinal adverse events were more common in those  previously exposed",
      "page": 54
    },
    {
      "level": "H2",
      "text": "to placebo (38.2%) than in those previously exposed to Exelon® (27.5%).",
      "page": 54
    },
    {
      "level": "H2",
      "text": "Adverse events that occurred in ≥ 5% of patients in the entire study cohort are",
      "page": 54
    },
    {
      "level": "H2",
      "text": "listed in the following sponsor table. Nausea, vomiting, and tremor were all more",
      "page": 54
    },
    {
      "level": "H2",
      "text": "common in those previously exposed to placebo than in those previously",
      "page": 54
    },
    {
      "level": "H2",
      "text": "exposed to Exelon®.",
      "page": 54
    },
    {
      "level": "H2",
      "text": "The incidence of adverse events potentially indicating a worsening in the",
      "page": 54
    },
    {
      "level": "H2",
      "text": "symptoms of Parkinson’s Disease was 18.0% overall, 26.0% in those previously",
      "page": 54
    },
    {
      "level": "H2",
      "text": "exposed to placebo, and 13.3% in those previously exposed to Exelon®. The",
      "page": 54
    },
    {
      "level": "H2",
      "text": "most common of these adverse events was tremor which had an incidence of",
      "page": 54
    },
    {
      "level": "H2",
      "text": "6.9% overall, 12.2% in those previously exposed to placebo, and 3.8% in those",
      "page": 54
    },
    {
      "level": "H2",
      "text": "previously exposed to Exelon®. Worsening of Parkinson’s Disease had an",
      "page": 54
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 55
    },
    {
      "level": "H2",
      "text": "incidence of 3.6% overall, 4.1% in those previously exposed to placebo, and",
      "page": 55
    },
    {
      "level": "H2",
      "text": "3.3% in those previously exposed to Exelon®.",
      "page": 55
    },
    {
      "level": "H2",
      "text": "8.2.5 Deaths, Serious Adverse Events, And Discontinuations Due To Adverse",
      "page": 55
    },
    {
      "level": "H2",
      "text": "Events",
      "page": 55
    },
    {
      "level": "H2",
      "text": "The overall incidence of deaths, serious adverse events, and adverse event",
      "page": 55
    },
    {
      "level": "H2",
      "text": "discontinuations in this study is summarized in the following table, which I have",
      "page": 55
    },
    {
      "level": "H2",
      "text": "copied from the submission:",
      "page": 55
    },
    {
      "level": "H2",
      "text": "A full listing of deaths that occurred in this study is in the following table, which I",
      "page": 55
    },
    {
      "level": "H2",
      "text": "have copied from the submission.",
      "page": 55
    },
    {
      "level": "H2",
      "text": "I have read the narratives for each death. None can  be clearly linked to study",
      "page": 55
    },
    {
      "level": "H2",
      "text": "drug; all appear to be due to intercurrent illnesses common in the study",
      "page": 55
    },
    {
      "level": "H2",
      "text": "population.",
      "page": 55
    },
    {
      "level": "H2",
      "text": "As noted above, 17.1% of patients enrolled in this study experienced a serious",
      "page": 55
    },
    {
      "level": "H2",
      "text": "adverse event, and 15.1% of patients enrolled experienced an adverse event that",
      "page": 55
    },
    {
      "level": "H2",
      "text": "warranted treatment discontinuation.",
      "page": 55
    },
    {
      "level": "H2",
      "text": "The most frequent adverse events leading to treatment discontinuation were as",
      "page": 55
    },
    {
      "level": "H2",
      "text": "follows, based on treatment assignment in the earlier double-blind study.",
      "page": 55
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 56
    },
    {
      "level": "H3",
      "text": "Adverse Event Leading To Discontinuation",
      "page": 56
    },
    {
      "level": "H2",
      "text": "I have read the listings and narratives for serious adverse events and",
      "page": 56
    },
    {
      "level": "H2",
      "text": "discontinuations due to adverse events. With the exception of those events that",
      "page": 56
    },
    {
      "level": "H2",
      "text": "could be attributed to the cholinomimetic effects of Exelon®, the adverse events",
      "page": 56
    },
    {
      "level": "H2",
      "text": "describe are all consistent with intercurrent illnesses that are common in this",
      "page": 56
    },
    {
      "level": "H2",
      "text": "population.",
      "page": 56
    },
    {
      "level": "H2",
      "text": "8.2.6 Laboratory Data",
      "page": 56
    },
    {
      "level": "H2",
      "text": "No laboratory testing was performed during the open-label extension phase of",
      "page": 56
    },
    {
      "level": "H2",
      "text": "this study.",
      "page": 56
    },
    {
      "level": "H2",
      "text": "8.2.7 Vital Signs And Weight",
      "page": 56
    },
    {
      "level": "H2",
      "text": "Mean changes from baseline in vital sign parameters and weight, and the",
      "page": 56
    },
    {
      "level": "H2",
      "text": "proportion of patients with notable vital sign or weight abnormalities have been",
      "page": 56
    },
    {
      "level": "H2",
      "text": "summarized in tabular form by the sponsor. These changes were small.",
      "page": 56
    },
    {
      "level": "H2",
      "text": "8.2.8 Electrocardiograms",
      "page": 56
    },
    {
      "level": "H2",
      "text": "No electrocardiograms were performed during this study.",
      "page": 56
    },
    {
      "level": "H2",
      "text": "8.2.9 UPDRS Part III Scores",
      "page": 56
    },
    {
      "level": "H2",
      "text": "Patients enrolled in the open-label extension study worsened by a mean (±",
      "page": 56
    },
    {
      "level": "H2",
      "text": "standard deviation) of 1.8 points (± 9.6 points) on the total UPDRS Part III score.",
      "page": 56
    },
    {
      "level": "H2",
      "text": "Individual tremor score worsened by a mean (± standard deviation) of 0.1 points",
      "page": 56
    },
    {
      "level": "H2",
      "text": "(± 2.3 points).",
      "page": 56
    },
    {
      "level": "H1",
      "text": "8.3 Sponsor’s Conclusions Regarding Safety",
      "page": 56
    },
    {
      "level": "H2",
      "text": "In patients treated with Exelon® or placebo in Study 2311, the safety and",
      "page": 56
    },
    {
      "level": "H2",
      "text": "tolerability of Exelon® in a dose of 3 to 12 mg/day in Study 2311E1 remained",
      "page": 56
    },
    {
      "level": "H2",
      "text": "favorable, with no new unexpected adverse events reported and no clinically",
      "page": 56
    },
    {
      "level": "H2",
      "text": "significant worsening of the motor symptoms of Parkinson’s Disease. The",
      "page": 56
    },
    {
      "level": "H2",
      "text": "tolerability profile of profile of Exelon® did not change over the 24-week open-",
      "page": 56
    },
    {
      "level": "H2",
      "text": "label extension study.",
      "page": 56
    },
    {
      "level": "H1",
      "text": "8.4 Reviewer’s Comments",
      "page": 56
    },
    {
      "level": "H2",
      "text": "I agree with the sponsor’s conclusions",
      "page": 56
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 57
    },
    {
      "level": "H1",
      "text": "9. Study 2314 (Non-Interventional Validation Study)",
      "page": 57
    },
    {
      "level": "H2",
      "text": "Note that the study report contained in this submission is an interim report which is",
      "page": 57
    },
    {
      "level": "H2",
      "text": "confined to the validation of various study instruments in Parkinson’s Disease Dementia",
      "page": 57
    },
    {
      "level": "H2",
      "text": "alone, whereas the original study protocol planned to validate these instruments in",
      "page": 57
    },
    {
      "level": "H2",
      "text": "vascular dementia as well. The description of the study protocol and results below is,",
      "page": 57
    },
    {
      "level": "H2",
      "text": "therefore, also confined to the validation of these study instruments in Parkinson’s",
      "page": 57
    },
    {
      "level": "H2",
      "text": "Disease Dementia alone.",
      "page": 57
    },
    {
      "level": "H1",
      "text": "9.1 Protocol",
      "page": 57
    },
    {
      "level": "H2",
      "text": "9.1.1 Title",
      "page": 57
    },
    {
      "level": "H2",
      "text": "A 4-Week, Non-Interventional, Cross-Sectional, Multicenter Study To Assess The",
      "page": 57
    },
    {
      "level": "H2",
      "text": "Validity Of Various Assessment Scales Measuring Cognition, Executive Function,",
      "page": 57
    },
    {
      "level": "H2",
      "text": "Behavior And Activities Of Daily Living In Patients With Mild To Moderate",
      "page": 57
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease Dementia",
      "page": 57
    },
    {
      "level": "H2",
      "text": "9.1.2 Objectives",
      "page": 57
    },
    {
      "level": "H2",
      "text": "9.1.2.1 Primary",
      "page": 57
    },
    {
      "level": "H2",
      "text": "9.1.2.2 Secondary",
      "page": 57
    },
    {
      "level": "H2",
      "text": "9.1.3 Design",
      "page": 57
    },
    {
      "level": "H2",
      "text": "Non-interventional cross-section study",
      "page": 57
    },
    {
      "level": "H2",
      "text": "9.1.4 Duration",
      "page": 57
    },
    {
      "level": "H2",
      "text": "4 weeks",
      "page": 57
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 58
    },
    {
      "level": "H2",
      "text": "9.1.5 Sample Size",
      "page": 58
    },
    {
      "level": "H2",
      "text": "The planned sample size was 100 patients, comprising 50 patients with",
      "page": 58
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease Dementia and 50 patients with Alzheimer’s Disease.",
      "page": 58
    },
    {
      "level": "H2",
      "text": "9.1.6 Main Inclusion Criteria",
      "page": 58
    },
    {
      "level": "H2",
      "text": "9.1.7 Study Schedule",
      "page": 58
    },
    {
      "level": "H2",
      "text": "The study schedule is summarized in the following table, which I have copied",
      "page": 58
    },
    {
      "level": "H2",
      "text": "from the submission.",
      "page": 58
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 59
    },
    {
      "level": "H1",
      "text": "9.1.8 Assessment Scales To Be Validated",
      "page": 59
    },
    {
      "level": "H2",
      "text": "9.1.9 Assessments Used For Staging",
      "page": 59
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 60
    },
    {
      "level": "H1",
      "text": "9.2 Main Results",
      "page": 60
    },
    {
      "level": "H2",
      "text": "9.2.1 Patient Disposition",
      "page": 60
    },
    {
      "level": "H2",
      "text": "Patient disposition by dementia type and Mini-Mental Status Examination stratum",
      "page": 60
    },
    {
      "level": "H2",
      "text": "is summarized in the following table, which I have copied from the submission.",
      "page": 60
    },
    {
      "level": "H1",
      "text": "9.2.2 Demographic And Other Baseline Characteristics",
      "page": 60
    },
    {
      "level": "H2",
      "text": "These are summarized in the next table, which I have copied from the",
      "page": 60
    },
    {
      "level": "H2",
      "text": "submission.",
      "page": 60
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 61
    },
    {
      "level": "H2",
      "text": "9.2.3 Primary Analysis Results",
      "page": 61
    },
    {
      "level": "H2",
      "text": "The sponsor table below is intended to illustrate the ability of the mean ADAS-",
      "page": 61
    },
    {
      "level": "H2",
      "text": "Cog score at baseline to differentiate between mild and moderate Parkinson’s",
      "page": 61
    },
    {
      "level": "H2",
      "text": "Disease Dementia (and Alzheimer’s Disease), based on a t-test and supported",
      "page": 61
    },
    {
      "level": "H2",
      "text": "by an analysis of variance with severity group and center as fixed effects.",
      "page": 61
    },
    {
      "level": "H2",
      "text": "The sponsor points out that the mean ADAS-Cog score at baseline shows a",
      "page": 61
    },
    {
      "level": "H2",
      "text": "distinct separation between mild and moderate patients in both the Parkinson’s",
      "page": 61
    },
    {
      "level": "H2",
      "text": "Disease Dementia and Alzheimer’s Disease groups, with a similar variance",
      "page": 61
    },
    {
      "level": "H2",
      "text": "associated with the mean in each dementia type and severity. The difference in",
      "page": 61
    },
    {
      "level": "H2",
      "text": "mean ADAS-Cog score between the mild and moderate groups was statistically",
      "page": 61
    },
    {
      "level": "H2",
      "text": "significant for each dementia type.",
      "page": 61
    },
    {
      "level": "H2",
      "text": "The size of the mean difference between Mini-Mental Status Examination strata",
      "page": 61
    },
    {
      "level": "H2",
      "text": "was also examined using a Cohen’s effect size computation. Using that",
      "page": 61
    },
    {
      "level": "H2",
      "text": "computation, effect sizes of 0.2, 0.5, and 0.8 are generally considered small,",
      "page": 61
    },
    {
      "level": "H2",
      "text": "medium, and large, respectively. Cohen’s effect size for the mean difference",
      "page": 61
    },
    {
      "level": "H2",
      "text": "between disease severities by dementia type, as determined by the sponsor, is in",
      "page": 61
    },
    {
      "level": "H2",
      "text": "the following table; while this effect size was larger for the Alzheimer’s Disease",
      "page": 61
    },
    {
      "level": "H2",
      "text": "group, it remained large for the group with Parkinson’s Disease Dementia as",
      "page": 61
    },
    {
      "level": "H2",
      "text": "well. These results also suggest that the ADAS-Cog is a scale that can produce a",
      "page": 61
    },
    {
      "level": "H2",
      "text": "good separation between Mini-Mental Status Examination strata in the patients",
      "page": 61
    },
    {
      "level": "H2",
      "text": "studied.",
      "page": 61
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 62
    },
    {
      "level": "H2",
      "text": "The test-retest reliability of the ADAS-Cog in this population was evaluated by",
      "page": 62
    },
    {
      "level": "H2",
      "text": "determining the correlation coefficient between the ADAS-Cog value at baseline",
      "page": 62
    },
    {
      "level": "H2",
      "text": "and that at Week 4 for each dementia type and severity; the results are in the",
      "page": 62
    },
    {
      "level": "H2",
      "text": "following table contained in the submission, which indicates, according to the",
      "page": 62
    },
    {
      "level": "H2",
      "text": "sponsor, that the correlation coefficients for the ADAS-Cog at baseline and Week",
      "page": 62
    },
    {
      "level": "H2",
      "text": "4 were strongly positive regardless of dementia type and severity; the sponsor",
      "page": 62
    },
    {
      "level": "H2",
      "text": "further states that although the confidence intervals for each correlation",
      "page": 62
    },
    {
      "level": "H2",
      "text": "coefficient were wide, even their lower limits showed a positive correlation.",
      "page": 62
    },
    {
      "level": "H1",
      "text": "9.2.4 Secondary Analyses",
      "page": 62
    },
    {
      "level": "H2",
      "text": "9.2.4.1 Ability Of Dementia-Rating Scales And Tests Other Than The ADAS-",
      "page": 62
    },
    {
      "level": "H2",
      "text": "Cog To Differentiate Between Alzheimer’s Disease Of Mild And Moderate",
      "page": 62
    },
    {
      "level": "H2",
      "text": "Severity (Assessment Of Criterion-Related Validity)",
      "page": 62
    },
    {
      "level": "H2",
      "text": "The ability of dementia rating scales and tests other than the ADAS-Cog to",
      "page": 62
    },
    {
      "level": "H2",
      "text": "differentiate between mild and moderate severity Parkinson’s Disease Dementia",
      "page": 62
    },
    {
      "level": "H2",
      "text": "and Alzheimer’s Disease were evaluated as with the ADAS-Cog by comparing",
      "page": 62
    },
    {
      "level": "H2",
      "text": "the mean values obtained for each severity category at baseline and at Week 4,",
      "page": 62
    },
    {
      "level": "H2",
      "text": "using a t-test. The results are in the following table, which indicate that for both",
      "page": 62
    },
    {
      "level": "H2",
      "text": "types of dementia, the separation between mild and moderate severities was",
      "page": 62
    },
    {
      "level": "H2",
      "text": "nominally statistically significant for the ADCS-ADL, Ten-Point Clock Test,",
      "page": 62
    },
    {
      "level": "H2",
      "text": "Trailmaking Test A, and D-KEFS Verbal Fluency Test.",
      "page": 62
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 63
    },
    {
      "level": "H2",
      "text": "The differences for other measures are in the above table.",
      "page": 63
    },
    {
      "level": "H2",
      "text": "Test-retest reliability by dementia type and Mini-Mental Status Examination",
      "page": 63
    },
    {
      "level": "H2",
      "text": "stratum is summarized in the following table, taken from the submission;",
      "page": 63
    },
    {
      "level": "H2",
      "text": "reliability was determined, as with the ADAS-Cog by calculating correlation",
      "page": 63
    },
    {
      "level": "H2",
      "text": "coefficients based on the baseline and Week 4 scores . The correlations were",
      "page": 63
    },
    {
      "level": "H2",
      "text": "best for the ADCS-ADL and Neuropsychiatry Inventory-10 for both populations.",
      "page": 63
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 64
    },
    {
      "level": "H2",
      "text": "9.2.4.2 Comparison Of Scores On Dementia Rating Scales In Patients With",
      "page": 64
    },
    {
      "level": "H2",
      "text": "Alzheimer’s Disease Versus Parkinson’s Disease Dementia",
      "page": 64
    },
    {
      "level": "H2",
      "text": "The total scores at baseline in the 2 populations were compared as indicated in",
      "page": 64
    },
    {
      "level": "H2",
      "text": "the following table. The sponsor points out that statistically significant differences",
      "page": 64
    },
    {
      "level": "H2",
      "text": "between the 2 populations were not apparent except for the ADCS-ADL score.",
      "page": 64
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 65
    },
    {
      "level": "H2",
      "text": "The sponsor has performed a factor analysis of the ADAS-Cog sub-item scores",
      "page": 65
    },
    {
      "level": "H2",
      "text": "at baseline for the Parkinson’s Disease Dementia and Alzheimer’s Disease",
      "page": 65
    },
    {
      "level": "H2",
      "text": "populations, as indicated in the following table, taken from the submission. The",
      "page": 65
    },
    {
      "level": "H2",
      "text": "sponsor has observed that the sub-items group differently in each population,",
      "page": 65
    },
    {
      "level": "H2",
      "text": "which may indicate a different profile of cognitive impairment. The sponsor does",
      "page": 65
    },
    {
      "level": "H2",
      "text": "acknowledge that the sample sizes were small for these analyses.",
      "page": 65
    },
    {
      "level": "H2",
      "text": "9.2.4.3 Convergent And Divergent Construct Validity Of The ADAS-Cog In",
      "page": 65
    },
    {
      "level": "H2",
      "text": "Patients With Alzheimer’s Disease And With Parkinson’s Disease Dementia",
      "page": 65
    },
    {
      "level": "H2",
      "text": "The degree of association between the ADAS-Cog and other scales was",
      "page": 65
    },
    {
      "level": "H2",
      "text": "explored by performing a correlation test between the ADAS-Cog scores and",
      "page": 65
    },
    {
      "level": "H2",
      "text": "those of each of the other scales at baseline. The sponsor considers the results,",
      "page": 65
    },
    {
      "level": "H2",
      "text": "summarized in the table below, to indicate at least a moderate correlation of the",
      "page": 65
    },
    {
      "level": "H2",
      "text": "ADAS-Cog with all assessments other than the Neuropsychiatry Inventory and",
      "page": 65
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 66
    },
    {
      "level": "H2",
      "text": "Neuropsychiatry Inventory-Distress. Correlation was best between the ADAS-",
      "page": 66
    },
    {
      "level": "H2",
      "text": "Cog and Mini-Mental Status Examination, in both populations.",
      "page": 66
    },
    {
      "level": "H1",
      "text": "9.3 Sponsor’s Conclusions",
      "page": 66
    },
    {
      "level": "H2",
      "text": "The following is a summary of the sponsor’s conclusions:",
      "page": 66
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 67
    },
    {
      "level": "H1",
      "text": "10. Summary Of Earlier Meeting Between Division And Sponsor",
      "page": 67
    },
    {
      "level": "H1",
      "text": "Regarding This Application.",
      "page": 67
    },
    {
      "level": "H2",
      "text": "A meeting was held with the sponsor on May 18, 2005, at which the results of",
      "page": 67
    },
    {
      "level": "H2",
      "text": "Study 2311 (EXPRESS Study) were discussed in outline and on a preliminary",
      "page": 67
    },
    {
      "level": "H2",
      "text": "basis, in the context of a sponsor proposal to expand the current indication for",
      "page": 67
    },
    {
      "level": "H2",
      "text": "Exelon® to include “the treatment of mild to moderate dementia associated with",
      "page": 67
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease.”",
      "page": 67
    },
    {
      "level": "H2",
      "text": "The following is a summary of the salient views conveyed by the sponsor’s team",
      "page": 67
    },
    {
      "level": "H2",
      "text": "at that meeting.",
      "page": 67
    },
    {
      "level": "H2",
      "text": "The Division’s key concerns about an expansion of the current claim for",
      "page": 67
    },
    {
      "level": "H2",
      "text": "rivastigmine to include dementia associated with Parkinson’s Disease, especially",
      "page": 67
    },
    {
      "level": "H2",
      "text": "on the basis of the results of the EXPRESS study alone, were as follows",
      "page": 67
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 68
    },
    {
      "level": "H2",
      "text": "The Division was of the view that the entity of dementia associated with",
      "page": 68
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease should be discussed at a meeting of the Peripheral and",
      "page": 68
    },
    {
      "level": "H2",
      "text": "Central Nervous Systems Drugs Advisory Committee. The sponsor proposed",
      "page": 68
    },
    {
      "level": "H2",
      "text": "submitting a Supplemental NDA based on efficacy data from the EXPRESS",
      "page": 68
    },
    {
      "level": "H2",
      "text": "Study only, with a request for a standard review and the possibility of holding a",
      "page": 68
    },
    {
      "level": "H2",
      "text": "meeting of the Advisory Committee during the course of that review was",
      "page": 68
    },
    {
      "level": "H2",
      "text": "discussed.",
      "page": 68
    },
    {
      "level": "H2",
      "text": "The Division was, very shortly after the meeting, to discuss internally whether it",
      "page": 68
    },
    {
      "level": "H2",
      "text": "would be prepared to file a Supplemental NDA for rivastigmine in the treatment of",
      "page": 68
    },
    {
      "level": "H2",
      "text": "dementia associated with Parkinson’s Disease, based on efficacy data derived",
      "page": 68
    },
    {
      "level": "H2",
      "text": "from the EXPRESS Study alone, given the proposed common mechanism of",
      "page": 68
    },
    {
      "level": "H2",
      "text": "action of rivastigmine in both dementia associated with Parkinson’s Disease and",
      "page": 68
    },
    {
      "level": "H2",
      "text": "Alzheimer’s Disease, and was to inform the sponsor of its view shortly.",
      "page": 68
    },
    {
      "level": "H2",
      "text": "On May 24, 2005, the Division informed the sponsor that it would accept the filing",
      "page": 68
    },
    {
      "level": "H2",
      "text": "of a Supplemental NDA for Exelon® in the treatment of dementia associated with",
      "page": 68
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease based on the results of the EXPRESS Study alone and that",
      "page": 68
    },
    {
      "level": "H2",
      "text": "review of  that application would include a discussion with the Peripheral and",
      "page": 68
    },
    {
      "level": "H2",
      "text": "Central Nervous Systems Drugs Advisory Committee during the 10-month review",
      "page": 68
    },
    {
      "level": "H2",
      "text": "period.",
      "page": 68
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 69
    },
    {
      "level": "H1",
      "text": "11. Sponsor’s Current View Of Dementia Associated With",
      "page": 69
    },
    {
      "level": "H1",
      "text": "Parkinson’s Disease, And Appropriateness Of ADAS-Cog And",
      "page": 69
    },
    {
      "level": "H1",
      "text": "ADCS-ADL In Evaluating Treatment Effects In Dementia",
      "page": 69
    },
    {
      "level": "H1",
      "text": "Associated With Parkinson’s Disease",
      "page": 69
    },
    {
      "level": "H2",
      "text": "Separate independent expert reports have been commissioned by the sponsor to",
      "page": 69
    },
    {
      "level": "H2",
      "text": "address each of these 2 subjects. The contents of these reports, with which the",
      "page": 69
    },
    {
      "level": "H2",
      "text": "sponsor appears to concur, are summarized below. Note that the sponsor has",
      "page": 69
    },
    {
      "level": "H2",
      "text": "supplemented the results of the second of the reports below with the conclusions",
      "page": 69
    },
    {
      "level": "H2",
      "text": "drawn from Study 2314.",
      "page": 69
    },
    {
      "level": "H1",
      "text": "11.1 Dementia Associated With Parkinson’s Disease (Expert Report:",
      "page": 69
    },
    {
      "level": "H1",
      "text": "Diagnosing Dementia Associated With Parkinson’s Disease And",
      "page": 69
    },
    {
      "level": "H1",
      "text": "Distinguishing It From Alzheimer’s Disease)",
      "page": 69
    },
    {
      "level": "H2",
      "text": "The report has been prepared by 3 academics at the request of the sponsor.",
      "page": 69
    },
    {
      "level": "H2",
      "text": "These individuals are Professors J. Cummings, M. Emre, and C. W. Olanow.",
      "page": 69
    },
    {
      "level": "H2",
      "text": "In the report they have provided their opinion in 2 areas",
      "page": 69
    },
    {
      "level": "H2",
      "text": "They have concluded that",
      "page": 69
    },
    {
      "level": "H2",
      "text": "The basis for their conclusions, as stated in the report, is provided under the",
      "page": 69
    },
    {
      "level": "H2",
      "text": "headings below, which are the same as those used by the authors of the report;",
      "page": 69
    },
    {
      "level": "H2",
      "text": "Please see the text of the report for full details.  Note that although many",
      "page": 69
    },
    {
      "level": "H2",
      "text": "publications are cited in the report, full citations are provided for only some of",
      "page": 69
    },
    {
      "level": "H2",
      "text": "those publications; also note that some publications cited are untraceable",
      "page": 69
    },
    {
      "level": "H2",
      "text": "through standard search engines.",
      "page": 69
    },
    {
      "level": "H2",
      "text": "11.1.1 Prevalence And Incidence Of Dementia Associated With Parkinson’s",
      "page": 69
    },
    {
      "level": "H2",
      "text": "Disease",
      "page": 69
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 70
    },
    {
      "level": "H2",
      "text": "• Incidence studies, which are relatively free of survival bias indicate a 4-6",
      "page": 70
    },
    {
      "level": "H2",
      "text": "11.1.2 Risk Factors For Dementia Associated With Parkinson’s Disease",
      "page": 70
    },
    {
      "level": "H2",
      "text": "11.1.3 Genetic Distinctions Between Alzheimer’s Disease And Parkinson’s",
      "page": 70
    },
    {
      "level": "H2",
      "text": "Disease",
      "page": 70
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 71
    },
    {
      "level": "H2",
      "text": "• There is no excess of Alzheimer’s Disease among probands with",
      "page": 71
    },
    {
      "level": "H3",
      "text": "Genetic Feature",
      "page": 71
    },
    {
      "level": "H3",
      "text": "Dementia Associated with Parkinson’s Disease",
      "page": 71
    },
    {
      "level": "H3",
      "text": "Alzheimer’s Disease",
      "page": 71
    },
    {
      "level": "H2",
      "text": "11.1.4 Neuropathological Distinctions Between Alzheimer’s Disease And",
      "page": 71
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease",
      "page": 71
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 72
    },
    {
      "level": "H2",
      "text": "• While the pathological abnormalities characteristic of Alzheimer’s Disease",
      "page": 72
    },
    {
      "level": "H2",
      "text": "Pathological Feature",
      "page": 72
    },
    {
      "level": "H2",
      "text": "Dementia Associated with",
      "page": 72
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease",
      "page": 72
    },
    {
      "level": "H2",
      "text": "Alzheimer’s Disease",
      "page": 72
    },
    {
      "level": "H1",
      "text": "11.1.5 Neuroimaging In Dementia Associated With Parkinson’s Disease",
      "page": 72
    },
    {
      "level": "H2",
      "text": "Only limited neuroimaging studies have been done in dementia associated with",
      "page": 72
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease.",
      "page": 72
    },
    {
      "level": "H2",
      "text": "Preliminary MRI observations suggest that while atrophy of the temporal lobes,",
      "page": 72
    },
    {
      "level": "H2",
      "text": "including the hippocampus and parahippocampal gyrus, is more severe in",
      "page": 72
    },
    {
      "level": "H2",
      "text": "patients with Alzheimer’s Disease, severe atrophy of the thalamus and occipital",
      "page": 72
    },
    {
      "level": "H2",
      "text": "lobes is more characteristic of Parkinson’s Disease.",
      "page": 72
    },
    {
      "level": "H2",
      "text": "Functional imaging studies (single-photon emission computerized tomography;",
      "page": 72
    },
    {
      "level": "H2",
      "text": "positron emission tomography) using radiolabeled ligands which provide a",
      "page": 72
    },
    {
      "level": "H2",
      "text": "measure of pre-synaptic dopaminergic neurons and terminals have revealed",
      "page": 72
    },
    {
      "level": "H2",
      "text": "significant reductions in striatal uptake or binding of these ligands, as compared",
      "page": 72
    },
    {
      "level": "H2",
      "text": "with patients who have Alzheimer’s Disease or controls.",
      "page": 72
    },
    {
      "level": "H2",
      "text": "11.1.6 Neuropsychological Differences Between Dementia Associated With",
      "page": 72
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease And Alzheimer’s Disease",
      "page": 72
    },
    {
      "level": "H2",
      "text": "These differences are summarized in the following table, which I have modified",
      "page": 72
    },
    {
      "level": "H2",
      "text": "slightly, for the sake of clarity, from one contained in the submission.",
      "page": 72
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Neuropsychological Domain",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Dementia Associated with Parkinson’s Disease",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Alzheimer’s Disease",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Memory",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Executive function deficit",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Language deficit",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Visuospatial deficits",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Bradyphrenia",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Fluctuation in attention",
      "page": 73
    },
    {
      "level": "H1",
      "text": "11.1.7 Distinction Between Dementia Associated With Parkinson’s Disease And",
      "page": 73
    },
    {
      "level": "H2",
      "text": "Alzheimer’s Disease Based On Non-Cognitive Clinical Features",
      "page": 73
    },
    {
      "level": "H2",
      "text": "These differences are summarized in the following table, which I have modified,",
      "page": 73
    },
    {
      "level": "H2",
      "text": "for the sake of clarity, from one contained in the submission.",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Non-Cognitive Feature",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Dementia Associated with Parkinson’s",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Disease",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Alzheimer’s Disease",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Motor signs of Parkinson’s Disease",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Neuroleptic sensitivity",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Autonomic dysfunction",
      "page": 73
    },
    {
      "level": "H3",
      "text": "REM sleep behavior disorder",
      "page": 73
    },
    {
      "level": "H2",
      "text": "11.1.8 Parkinson’s Disease Can Be Distinguished From Alzheimer’s Disease By",
      "page": 73
    },
    {
      "level": "H2",
      "text": "A Practitioner",
      "page": 73
    },
    {
      "level": "H2",
      "text": "The currently available diagnostic criteria for dementia associated with",
      "page": 73
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease are those contained in DSM-IV. According to the authors of",
      "page": 73
    },
    {
      "level": "H2",
      "text": "the report, all major criteria, which are listed below, should be present for a",
      "page": 73
    },
    {
      "level": "H2",
      "text": "diagnosis to be made.",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 74
    },
    {
      "level": "H2",
      "text": "A medical practitioner can apply these criteria easily.",
      "page": 74
    },
    {
      "level": "H1",
      "text": "11.2 Appropriateness Of Using The ADAS-Cog And ADCS-ADL As",
      "page": 74
    },
    {
      "level": "H1",
      "text": "Outcome Measures In Dementia Associated With Parkinson’s Disease",
      "page": 74
    },
    {
      "level": "H2",
      "text": "An expert report prepared by Philip D. Harvey, PhD, has been provided in this",
      "page": 74
    },
    {
      "level": "H2",
      "text": "submission. Although this report addresses both the use of the ADAS-Cog and",
      "page": 74
    },
    {
      "level": "H2",
      "text": "ADCS-ADL in this condition, it is entitled: “Reliability and Validity of the",
      "page": 74
    },
    {
      "level": "H2",
      "text": "Alzheimer’s Disease Assessment Scale – Cognitive Subscale in Clinical Trials for",
      "page": 74
    },
    {
      "level": "H2",
      "text": "Dementia Associated with Parkinson’s Disease.”",
      "page": 74
    },
    {
      "level": "H2",
      "text": "The report was created partly in response to comments made by the European",
      "page": 74
    },
    {
      "level": "H2",
      "text": "Agency for the Evaluation of Medicinal Products/Committee for Proprietary",
      "page": 74
    },
    {
      "level": "H2",
      "text": "Medicinal Products after review of an earlier version of the protocol for the non-",
      "page": 74
    },
    {
      "level": "H2",
      "text": "interventional study 2314.",
      "page": 74
    },
    {
      "level": "H2",
      "text": "Note that this report, which was completed on October 28, 2004, does not cite",
      "page": 74
    },
    {
      "level": "H2",
      "text": "the results of either Study 2311 or Study 2314, and appears to have been",
      "page": 74
    },
    {
      "level": "H2",
      "text": "completed without taking these data into consideration. It is based on a review of",
      "page": 74
    },
    {
      "level": "H2",
      "text": "the medical literature (but that review does not include the published results of",
      "page": 74
    },
    {
      "level": "H2",
      "text": "Study 2311).",
      "page": 74
    },
    {
      "level": "H2",
      "text": "The contents of this report are briefly summarized below under the following",
      "page": 74
    },
    {
      "level": "H2",
      "text": "headings.",
      "page": 74
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 75
    },
    {
      "level": "H2",
      "text": "11.2.1 ADAS-Cog",
      "page": 75
    },
    {
      "level": "H2",
      "text": "11.2.1.1 ADAS-Cog In Alzheimer’s Disease",
      "page": 75
    },
    {
      "level": "H2",
      "text": "The author of the report states that the ADAS-Cog has the following properties",
      "page": 75
    },
    {
      "level": "H2",
      "text": "when used in Alzheimer’s Disease.",
      "page": 75
    },
    {
      "level": "H2",
      "text": "The author also points out that in efficacy studies in this population, the benefits",
      "page": 75
    },
    {
      "level": "H2",
      "text": "of active treatment are evaluated in relation to placebo groups which experience",
      "page": 75
    },
    {
      "level": "H2",
      "text": "a decline in cognition over the study; in some of these studies, the active",
      "page": 75
    },
    {
      "level": "H2",
      "text": "treatment group experienced no improvement relative to baseline. In other",
      "page": 75
    },
    {
      "level": "H2",
      "text": "words, a net benefit relative to placebo is assessed rather than an absolute",
      "page": 75
    },
    {
      "level": "H2",
      "text": "improvement with active treatment relative to baseline.",
      "page": 75
    },
    {
      "level": "H2",
      "text": "11.2.1.2 ADAS-Cog In Parkinson’s Disease Dementia",
      "page": 75
    },
    {
      "level": "H2",
      "text": "The following is a summary of what is stated by the author of this report.",
      "page": 75
    },
    {
      "level": "H2",
      "text": "11.2.1.2.1 Face Validity Of ADAS-Cog",
      "page": 75
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease Dementia is characterized by the following",
      "page": 75
    },
    {
      "level": "H2",
      "text": "While executive dysfunction is not well assessed by the ADAS-Cog, it is a feature",
      "page": 75
    },
    {
      "level": "H2",
      "text": "of both Alzheimer’s Disease and Parkinson’s Disease Dementia.",
      "page": 75
    },
    {
      "level": "H2",
      "text": "The ADAS-Cog is sufficient to evaluate episodic memory impairment in",
      "page": 75
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease Dementia and therefore captures critical features of that",
      "page": 75
    },
    {
      "level": "H2",
      "text": "condition.",
      "page": 75
    },
    {
      "level": "H2",
      "text": "11.2.1.2.2 Temporal Change In ADAS-Cog",
      "page": 75
    },
    {
      "level": "H2",
      "text": "The course of cognitive decline in Parkinson’s Disease Dementia has not been",
      "page": 75
    },
    {
      "level": "H2",
      "text": "adequately studied; existing published studies have a number of limitations. The",
      "page": 75
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 76
    },
    {
      "level": "H2",
      "text": "few treatment studies in this condition prior to Study 2311 suggest that the",
      "page": 76
    },
    {
      "level": "H2",
      "text": "cognitive change that occurs in Parkinson’s Disease Dementia over time is not",
      "page": 76
    },
    {
      "level": "H2",
      "text": "as rapid or extensive as that seen over a similar period in patients with",
      "page": 76
    },
    {
      "level": "H2",
      "text": "Alzheimer’s Disease.",
      "page": 76
    },
    {
      "level": "H2",
      "text": "11.2.1.2.3   Sensitivity To Impairment And To Effects Of Treatment",
      "page": 76
    },
    {
      "level": "H2",
      "text": "The very limited literature covering the use of the ADAS-Cog in Parkinson’s",
      "page": 76
    },
    {
      "level": "H2",
      "text": "Disease Dementia suggests that scores on that instrument  correlate with those",
      "page": 76
    },
    {
      "level": "H2",
      "text": "on the Mini-Mental Status Examination, suggesting that the ADAS-Cog is",
      "page": 76
    },
    {
      "level": "H2",
      "text": "sensitive to impairment in that condition. The limited literature available also",
      "page": 76
    },
    {
      "level": "H2",
      "text": "suggests that the ADAS-Cog is as sensitive to treatment effects in Parkinson’s",
      "page": 76
    },
    {
      "level": "H2",
      "text": "Disease Dementia as in Alzheimer’s Disease.",
      "page": 76
    },
    {
      "level": "H2",
      "text": "11.2.1.2.4 Criterion Validity: Clinically Relevant Differences",
      "page": 76
    },
    {
      "level": "H2",
      "text": "Based on the small number of published studies, treatment effects in Parkinson’s",
      "page": 76
    },
    {
      "level": "H2",
      "text": "Disease Dementia, as measured by the ADAS-Cog, are at least as large as",
      "page": 76
    },
    {
      "level": "H2",
      "text": "those in Alzheimer’s Disease and, therefore, at least as clinically meaningful.",
      "page": 76
    },
    {
      "level": "H2",
      "text": "11.2.2 ADCS-ADL",
      "page": 76
    },
    {
      "level": "H2",
      "text": "11.2.2.1 ADCS-ADL In Alzheimer’s Disease",
      "page": 76
    },
    {
      "level": "H2",
      "text": "The author highlights the following properties of the ADCS-ADL in Alzheimer’s",
      "page": 76
    },
    {
      "level": "H2",
      "text": "Disease, based on the published literature:",
      "page": 76
    },
    {
      "level": "H2",
      "text": "11.2.2.2 ADCS-ADL In Parkinson’s Disease Dementia",
      "page": 76
    },
    {
      "level": "H2",
      "text": "While there are no published studies of the use of the ADCS-ADL in Parkinson’s",
      "page": 76
    },
    {
      "level": "H2",
      "text": "Disease Dementia, the experience in Alzheimer’s Disease supports its use as a",
      "page": 76
    },
    {
      "level": "H2",
      "text": "“secondary” outcome measure in Parkinson’s Disease Dementia.",
      "page": 76
    },
    {
      "level": "H2",
      "text": "However, clinical changes in domains in Parkinson’s Disease other than",
      "page": 76
    },
    {
      "level": "H2",
      "text": "cognition can result in changes in performance on activities of daily living.",
      "page": 76
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 77
    },
    {
      "level": "H1",
      "text": "12. Financial Disclosure Certification",
      "page": 77
    },
    {
      "level": "H2",
      "text": "Financial disclosure information has been collected for the following studies:",
      "page": 77
    },
    {
      "level": "H2",
      "text": "2311, 2311E1, and 2314.",
      "page": 77
    },
    {
      "level": "H1",
      "text": "12.1 Components Of Certification",
      "page": 77
    },
    {
      "level": "H2",
      "text": "This certification provided by the sponsor has 2 components.",
      "page": 77
    },
    {
      "level": "H2",
      "text": "12.1.1 Certification Pertinent To Investigators/Sub-Investigators Who Declared",
      "page": 77
    },
    {
      "level": "H2",
      "text": "The sponsor has supplied a list of all such investigators and sub-investigators",
      "page": 77
    },
    {
      "level": "H2",
      "text": "who were involved in these studies. In regard to this list the sponsor has",
      "page": 77
    },
    {
      "level": "H2",
      "text": "• Certified that it has not entered into any financial agreement with the clinical",
      "page": 77
    },
    {
      "level": "H2",
      "text": "• Certified that each listed clinical investigator required to disclose to the",
      "page": 77
    },
    {
      "level": "H2",
      "text": "• Certified that no listed investigator was the recipient of significant payments of",
      "page": 77
    },
    {
      "level": "H2",
      "text": "This certification has been provided on FDA Form 3454.",
      "page": 77
    },
    {
      "level": "H2",
      "text": "12.1.2 Certification Pertinent To Investigators/Sub-Investigators With",
      "page": 77
    },
    {
      "level": "H2",
      "text": "The sponsor has provided the name of a single investigator participating in Study",
      "page": 77
    },
    {
      "level": "H2",
      "text": "2311 who had a disclosable financial interest. This investigator had received a",
      "page": 77
    },
    {
      "level": "H2",
      "text": "grant from the sponsor to conduct a study of rivastigmine in nursing home",
      "page": 77
    },
    {
      "level": "H2",
      "text": "patients with severe dementia.",
      "page": 77
    },
    {
      "level": "H2",
      "text": "This certification has been provided on FDA Form 3455.",
      "page": 77
    },
    {
      "level": "H1",
      "text": "12.2 Reviewer’s Comments",
      "page": 77
    },
    {
      "level": "H2",
      "text": "It appears unlikely that the financial arrangements disclosed above introduced",
      "page": 77
    },
    {
      "level": "H2",
      "text": "significant bias into the results of trials submitted with this application.",
      "page": 77
    },
    {
      "level": "H1",
      "text": "13. Site Inspection Report",
      "page": 77
    },
    {
      "level": "H2",
      "text": "Pending",
      "page": 77
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 78
    },
    {
      "level": "H1",
      "text": "14. Review Of Proposed Labeling",
      "page": 78
    },
    {
      "level": "H2",
      "text": "Deferred",
      "page": 78
    },
    {
      "level": "H1",
      "text": "15. Comments",
      "page": 78
    },
    {
      "level": "H1",
      "text": "15.1 General",
      "page": 78
    },
    {
      "level": "H2",
      "text": "In this supplemental New Drug Application, the sponsor is seeking the approval",
      "page": 78
    },
    {
      "level": "H2",
      "text": "of Exelon® (rivastigmine tartrate) capsules for the treatment of “mild to moderate",
      "page": 78
    },
    {
      "level": "H2",
      "text": "dementia associated with Parkinson’s Disease.” The putative entity of  “mild to",
      "page": 78
    },
    {
      "level": "H2",
      "text": "moderate dementia associated with Parkinson’s Disease” has also been referred",
      "page": 78
    },
    {
      "level": "H2",
      "text": "to, interchangeably, as “Parkinson’s Disease Dementia” in this application.",
      "page": 78
    },
    {
      "level": "H2",
      "text": "Exelon® is currently approved for marketing in this country, as both capsule and",
      "page": 78
    },
    {
      "level": "H2",
      "text": "oral solution formulations, for the treatment of mild to moderate dementia of the",
      "page": 78
    },
    {
      "level": "H2",
      "text": "Alzheimer’s type.",
      "page": 78
    },
    {
      "level": "H2",
      "text": "The sponsor has provided evidence from two completed clinical studies in",
      "page": 78
    },
    {
      "level": "H2",
      "text": "support of the efficacy and safety of Exelon® for the proposed new indication.",
      "page": 78
    },
    {
      "level": "H2",
      "text": "These are:",
      "page": 78
    },
    {
      "level": "H2",
      "text": "In addition, the sponsor has performed a non-interventional study (Study 2314) of",
      "page": 78
    },
    {
      "level": "H2",
      "text": "the validity of a number of assessment scales in the Parkinson’s Disease",
      "page": 78
    },
    {
      "level": "H2",
      "text": "Dementia (and vascular dementia); partial results for this study have been",
      "page": 78
    },
    {
      "level": "H2",
      "text": "submitted in this application.",
      "page": 78
    },
    {
      "level": "H1",
      "text": "15.2 Efficacy",
      "page": 78
    },
    {
      "level": "H2",
      "text": "15.2.1 Summary Of Study 2311",
      "page": 78
    },
    {
      "level": "H2",
      "text": "The results of a single randomized, double-blind, placebo-controlled study (also",
      "page": 78
    },
    {
      "level": "H2",
      "text": "referred to as the EXPRESS Study) of the efficacy of rivastigmine in the",
      "page": 78
    },
    {
      "level": "H2",
      "text": "proposed entity of Parkinson’s Disease Dementia or dementia associated with",
      "page": 78
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease has been submitted in this application.  The main features",
      "page": 78
    },
    {
      "level": "H2",
      "text": "of this study were as follows",
      "page": 78
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 79
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 80
    },
    {
      "level": "H2",
      "text": "Key efficacy results for this study were as follows",
      "page": 80
    },
    {
      "level": "H2",
      "text": "15.2.2 Sponsor’s View Of The Entity Of Parkinson’s Disease Dementia",
      "page": 80
    },
    {
      "level": "H2",
      "text": "(Dementia Associated With Parkinson’s Disease)",
      "page": 80
    },
    {
      "level": "H2",
      "text": "The sponsor’s view of the entity of dementia associated with Parkinson’s Disease",
      "page": 80
    },
    {
      "level": "H2",
      "text": "appears to be consistent with an expert report included in this submission. The",
      "page": 80
    },
    {
      "level": "H2",
      "text": "main conclusions of the expert report may be summarized as follows:",
      "page": 80
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 81
    },
    {
      "level": "H2",
      "text": "15.2.3 Implications Of Efficacy Results Of Study 2311 (EXPRESS Study)",
      "page": 81
    },
    {
      "level": "H2",
      "text": "Study 2311 may be considered “positive” in that it demonstrates the efficacy of",
      "page": 81
    },
    {
      "level": "H2",
      "text": "Exelon® in the study population based on prospectively-specified criteria for",
      "page": 81
    },
    {
      "level": "H2",
      "text": "success. The dual efficacy outcome measure paradigm used for demonstrating",
      "page": 81
    },
    {
      "level": "H2",
      "text": "the efficacy of Exelon® in this study is the same as used to demonstrate the",
      "page": 81
    },
    {
      "level": "H2",
      "text": "efficacy of drugs approved for the treatment of Alzheimer’s Disease (dementia of",
      "page": 81
    },
    {
      "level": "H2",
      "text": "the Alzheimer’s type).",
      "page": 81
    },
    {
      "level": "H2",
      "text": "However, the key regulatory question that needs to be addressed in the",
      "page": 81
    },
    {
      "level": "H1",
      "text": "context of  this application is whether the results of Study 2311 establish",
      "page": 81
    },
    {
      "level": "H1",
      "text": "that Exelon® is effective in the treatment of an entity (dementia associated",
      "page": 81
    },
    {
      "level": "H1",
      "text": "with Parkinson’s Disease [Parkinson’s Disease Dementia]) that is",
      "page": 81
    },
    {
      "level": "H1",
      "text": "sufficiently distinct from mild to moderate dementia of the Alzheimer’s type",
      "page": 81
    },
    {
      "level": "H1",
      "text": "[for the treatment of which Exelon® is already approved] to justify a",
      "page": 81
    },
    {
      "level": "H1",
      "text": "separate regulatory claim.",
      "page": 81
    },
    {
      "level": "H2",
      "text": "Note that for a drug to be approved for a specific condition the following must",
      "page": 81
    },
    {
      "level": "H2",
      "text": "generally be true",
      "page": 81
    },
    {
      "level": "H2",
      "text": "I will address the question (in bolded text) above, and several additional",
      "page": 81
    },
    {
      "level": "H2",
      "text": "questions under the following headings",
      "page": 81
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 82
    },
    {
      "level": "H2",
      "text": "15.2.3.1 Is Parkinson’s Disease Dementia (dementia associated with",
      "page": 82
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease) a distinct entity (i.e., distinct from Alzheimer’s Disease) and",
      "page": 82
    },
    {
      "level": "H2",
      "text": "do widely accepted, valid, and reliable criteria exist for its clinical diagnosis?",
      "page": 82
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 83
    },
    {
      "level": "H2",
      "text": "judged to be of direct pathophysiological consequence of Parkinson’s",
      "page": 83
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 84
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 85
    },
    {
      "level": "H2",
      "text": "15.2.3.2 What are the implications of the diagnostic criteria for dementia with",
      "page": 85
    },
    {
      "level": "H2",
      "text": "Lewy bodies for the entity of Parkinson’s Disease Dementia?",
      "page": 85
    },
    {
      "level": "H2",
      "text": "Another entity that combines dementia with features of Parkinson’s Disease is",
      "page": 85
    },
    {
      "level": "H2",
      "text": "dementia with Lewy bodies for which revised diagnostic criteria have recently",
      "page": 85
    },
    {
      "level": "H2",
      "text": "been proposed (see McKeith et al [2005] below). In the more recent medical",
      "page": 85
    },
    {
      "level": "H2",
      "text": "literature, this entity has generally been distinguished from Parkinson’s Disease",
      "page": 85
    },
    {
      "level": "H2",
      "text": "Dementia by the (arbitrary) “one-year rule” criterion where the onset of dementia",
      "page": 85
    },
    {
      "level": "H2",
      "text": "within 12 months of the onset of parkinsonism is stated to be consistent with",
      "page": 85
    },
    {
      "level": "H2",
      "text": "dementia with Lewy bodies whereas if parkinsonism has been present for more",
      "page": 85
    },
    {
      "level": "H2",
      "text": "than 12 months prior to the onset of dementia, the condition is considered to",
      "page": 85
    },
    {
      "level": "H2",
      "text": "represent Parkinson’s Disease Dementia. The neuropathological abnormalities",
      "page": 85
    },
    {
      "level": "H2",
      "text": "that underlie both conditions are considered to be similar with changes",
      "page": 85
    },
    {
      "level": "H2",
      "text": "considered distinctive for Parkinson’s Disease being combined with other",
      "page": 85
    },
    {
      "level": "H2",
      "text": "pathology, notably Alzheimer-type changes. Whether these entities are the same",
      "page": 85
    },
    {
      "level": "H2",
      "text": "disease or separate distinct entities is still a matter of some controversy, although",
      "page": 85
    },
    {
      "level": "H2",
      "text": "the consensus view appears to be that they are the same neurobiological entity",
      "page": 85
    },
    {
      "level": "H2",
      "text": "with clinical phenotypes that differ, based solely on the arbitrary “one-year rule.”",
      "page": 85
    },
    {
      "level": "H2",
      "text": "Note that the revised criteria for the diagnosis of dementia with Lewy bodies",
      "page": 85
    },
    {
      "level": "H2",
      "text": "include the following “central” (required) feature: “Dementia defined as",
      "page": 85
    },
    {
      "level": "H2",
      "text": "progressive cognitive decline of sufficient magnitude to interfere  with normal",
      "page": 85
    },
    {
      "level": "H2",
      "text": "social or occupational function. Prominent or persistent memory impairment may",
      "page": 85
    },
    {
      "level": "H2",
      "text": "not necessarily occur in the early stages, but is usually evident with progression.",
      "page": 85
    },
    {
      "level": "H2",
      "text": "Deficits on tests of attention, executive function, and visuospatial ability may be",
      "page": 85
    },
    {
      "level": "H2",
      "text": "especially prominent.” The publication that describes these revised diagnostic",
      "page": 85
    },
    {
      "level": "H2",
      "text": "criteria (McKeith et al [2005]) further states the following: “The cognitive profile of",
      "page": 85
    },
    {
      "level": "H2",
      "text": "dementia with Lewy bodies (DLB) comprises both cortical and subcortical",
      "page": 85
    },
    {
      "level": "H2",
      "text": "impairments with substantial attentional deficits and prominent executive and",
      "page": 85
    },
    {
      "level": "H2",
      "text": "visuospatial dysfunction.  A “double discrimination” can help differentiate DLB",
      "page": 85
    },
    {
      "level": "H2",
      "text": "from Alzheimer disease (AD), with relative preservation of confrontation naming",
      "page": 85
    },
    {
      "level": "H2",
      "text": "and short and medium term recall as well as recognition, and greater impairment",
      "page": 85
    },
    {
      "level": "H2",
      "text": "on verbal fluency, visual perception and performance tasks.” These cognitive",
      "page": 85
    },
    {
      "level": "H2",
      "text": "abnormalities are similar to those described by a number of authors as being",
      "page": 85
    },
    {
      "level": "H2",
      "text": "distinctive for Parkinson’s Disease Dementia",
      "page": 85
    },
    {
      "level": "H2",
      "text": "Thus the same (reportedly) distinctive clinical features may be common to both",
      "page": 85
    },
    {
      "level": "H2",
      "text": "dementia with Lewy bodies and Parkinson’s Disease Dementia, while both",
      "page": 85
    },
    {
      "level": "H2",
      "text": "entities may also have the same neuropathological basis.",
      "page": 85
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 86
    },
    {
      "level": "H2",
      "text": "15.2.3.3 Was the population enrolled in Study 2311 selected appropriately in the",
      "page": 86
    },
    {
      "level": "H2",
      "text": "context of the proposed new indication, such that the effects of Exelon® in that",
      "page": 86
    },
    {
      "level": "H2",
      "text": "population could be considered distinct from those already established as",
      "page": 86
    },
    {
      "level": "H2",
      "text": "occurring in patients with Alzheimer’s Disease?",
      "page": 86
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 87
    },
    {
      "level": "H2",
      "text": "The following were the corresponding changes seen in Study 2311",
      "page": 87
    },
    {
      "level": "H2",
      "text": "As noted earlier, in patients with Parkinson’s Disease who develop dementia,",
      "page": 87
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 88
    },
    {
      "level": "H2",
      "text": "15.2.3.4 Was the population enrolled in Study 2311 otherwise selected",
      "page": 88
    },
    {
      "level": "H2",
      "text": "appropriately?",
      "page": 88
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 89
    },
    {
      "level": "H2",
      "text": "computerized tomography or magnetic resonance scanning) was not",
      "page": 89
    },
    {
      "level": "H2",
      "text": "required prior to entry into the study. Study Case Report Forms do not",
      "page": 89
    },
    {
      "level": "H2",
      "text": "enrolled in Study 2311 were evaluated for “non-degenerative” causes",
      "page": 89
    },
    {
      "level": "H2",
      "text": "of dementia such as cerebrovascular lesions, brain tumors, subdural",
      "page": 89
    },
    {
      "level": "H2",
      "text": "hematomas, and communicating hydrocephalus in the absence of",
      "page": 89
    },
    {
      "level": "H2",
      "text": "brain imaging. Admittedly, those conditions are often associated",
      "page": 89
    },
    {
      "level": "H2",
      "text": "with additional symptoms and signs on neurological evaluation, but",
      "page": 89
    },
    {
      "level": "H2",
      "text": "a standard neurological evaluation can be more difficult than usual",
      "page": 89
    },
    {
      "level": "H2",
      "text": "to perform in patients with co-existing Parkinson’s Disease so that",
      "page": 89
    },
    {
      "level": "H2",
      "text": "subtle physical signs may not be detected.",
      "page": 89
    },
    {
      "level": "H2",
      "text": "15.2.3.5 Was the overall design of Study 2311 appropriate and were the primary",
      "page": 89
    },
    {
      "level": "H2",
      "text": "efficacy measures used suitable for evaluating the efficacy and safety of",
      "page": 89
    },
    {
      "level": "H2",
      "text": "rivastigmine in mild to moderate dementia associated with Parkinson’s Disease?",
      "page": 89
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 90
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 91
    },
    {
      "level": "H2",
      "text": "15.2.3.6 Could the apparent beneficial effects of Exelon® on cognition and/or",
      "page": 91
    },
    {
      "level": "H2",
      "text": "global function in Study 2311 have been due to a beneficial effect on the motor",
      "page": 91
    },
    {
      "level": "H2",
      "text": "manifestations of Parkinson’s Disease rather than on the dementia itself?",
      "page": 91
    },
    {
      "level": "H2",
      "text": "If there was a beneficial effect of Exelon® on specific motor manifestations of",
      "page": 91
    },
    {
      "level": "H2",
      "text": "Parkinson’s Disease such as bradykinesia or dysarthria, it is possible that such a",
      "page": 91
    },
    {
      "level": "H2",
      "text": "benefit may have been reflected in a beneficial effect on the ADAS-Cog and/or",
      "page": 91
    },
    {
      "level": "H2",
      "text": "ADCS-CGIC, in the absence of a true effect on the dementia itself",
      "page": 91
    },
    {
      "level": "H2",
      "text": "Such a possibility is unlikely for the following reasons",
      "page": 91
    },
    {
      "level": "H2",
      "text": "[Also note that the study procedures included a number of precautions to",
      "page": 91
    },
    {
      "level": "H2",
      "text": "minimize the effects of the motor manifestations of Parkinson’s Disease on the",
      "page": 91
    },
    {
      "level": "H2",
      "text": "efficacy assessments].",
      "page": 91
    },
    {
      "level": "H2",
      "text": "15.2.3.7  Do the results of Study 2311 warrant replication for a claim for the",
      "page": 91
    },
    {
      "level": "H2",
      "text": "treatment of dementia associated with Parkinson’s Disease to be granted?",
      "page": 91
    },
    {
      "level": "H2",
      "text": "All drugs approved by this Agency so far for the treatment of dementia of the",
      "page": 91
    },
    {
      "level": "H2",
      "text": "Alzheimer’s type (Alzheimer’s Disease) have been approved based on the",
      "page": 91
    },
    {
      "level": "H2",
      "text": "demonstration of the desired treatment effect in at least 2 adequate and well-",
      "page": 91
    },
    {
      "level": "H2",
      "text": "controlled trials; the same has applied to the approval of drugs for other discrete",
      "page": 91
    },
    {
      "level": "H2",
      "text": "clinical entities. This Division’s view so far is that the same principle must apply",
      "page": 91
    },
    {
      "level": "H2",
      "text": "to other types of dementia, unless they are variants or grades of severity of",
      "page": 91
    },
    {
      "level": "H2",
      "text": "Alzheimer’s Disease not subsumed under the current claim.",
      "page": 91
    },
    {
      "level": "H2",
      "text": "Therefore, if dementia associated with Parkinson’s Disease is indeed a form of",
      "page": 91
    },
    {
      "level": "H2",
      "text": "dementia that is distinct from Alzheimer’s Disease, it would be appropriate to",
      "page": 91
    },
    {
      "level": "H2",
      "text": "require that the results of Study 2311 be replicated.",
      "page": 91
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 92
    },
    {
      "level": "H2",
      "text": "15.2.3.8 References",
      "page": 92
    },
    {
      "level": "H2",
      "text": "The references, based upon which a number of the above comments have been",
      "page": 92
    },
    {
      "level": "H2",
      "text": "made are listed",
      "page": 92
    },
    {
      "level": "H3",
      "text": "Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in",
      "page": 92
    },
    {
      "level": "H3",
      "text": "Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a",
      "page": 92
    },
    {
      "level": "H3",
      "text": "Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol 2003;2:229-37",
      "page": 92
    },
    {
      "level": "H3",
      "text": "Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale",
      "page": 92
    },
    {
      "level": "H3",
      "text": "McKeith IG, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB",
      "page": 92
    },
    {
      "level": "H3",
      "text": "McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H,",
      "page": 92
    },
    {
      "level": "H3",
      "text": "Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O'Brien J, Playfer J, Reid W; International",
      "page": 92
    },
    {
      "level": "H3",
      "text": "Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurol 2004; 3:19-28",
      "page": 92
    },
    {
      "level": "H3",
      "text": "Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner",
      "page": 92
    },
    {
      "level": "H3",
      "text": "WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and",
      "page": 92
    },
    {
      "level": "H3",
      "text": "Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC.",
      "page": 92
    },
    {
      "level": "H1",
      "text": "15.3 Safety",
      "page": 92
    },
    {
      "level": "H2",
      "text": "Evidence for the safety of Exelon® in dementia associated with Parkinson’s",
      "page": 92
    },
    {
      "level": "H2",
      "text": "Disease is derived from 2 sources",
      "page": 92
    },
    {
      "level": "H2",
      "text": "15.3.1 Study 2311",
      "page": 92
    },
    {
      "level": "H2",
      "text": "This study has already been summarized above. Salient safety findings for this",
      "page": 92
    },
    {
      "level": "H2",
      "text": "study were as follows.",
      "page": 92
    },
    {
      "level": "H2",
      "text": "15.3.2 Study 2311E1",
      "page": 92
    },
    {
      "level": "H2",
      "text": "This was an 24-week open-label uncontrolled extension to Study 2311 intended",
      "page": 92
    },
    {
      "level": "H2",
      "text": "primarily to evaluate the safety and tolerability of Exelon® in the study",
      "page": 92
    },
    {
      "level": "H3",
      "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
      "page": 93
    },
    {
      "level": "H2",
      "text": "population. Patients given the option of enrolling in this study had either",
      "page": 93
    },
    {
      "level": "H2",
      "text": "completed the double-blind treatment phase of Study 2311 or discontinued early",
      "page": 93
    },
    {
      "level": "H2",
      "text": "during that study, but returned for all the remaining scheduled efficacy",
      "page": 93
    },
    {
      "level": "H2",
      "text": "assessments without significant protocol violations. Regardless of their previous",
      "page": 93
    },
    {
      "level": "H2",
      "text": "treatment assignment, patients enrolled in the extension study were all re-titrated",
      "page": 93
    },
    {
      "level": "H2",
      "text": "to a flexible dose of Exelon® that ranged from 1.5 mg BID to 6.0 mg BID, based",
      "page": 93
    },
    {
      "level": "H2",
      "text": "on tolerability.",
      "page": 93
    },
    {
      "level": "H2",
      "text": "433 patients enrolled in Study 2311 were eligible to enroll in Study 2311E1 of",
      "page": 93
    },
    {
      "level": "H2",
      "text": "whom 334 actually consented to participate and 273 completed the study. The",
      "page": 93
    },
    {
      "level": "H2",
      "text": "adverse event profile of Exelon® in Study 2311 was broadly similar to that seen",
      "page": 93
    },
    {
      "level": "H2",
      "text": "in Study 2311E1",
      "page": 93
    },
    {
      "level": "H1",
      "text": "16. Conclusions",
      "page": 93
    },
    {
      "level": "H2",
      "text": "Deferred, pending discussion of this application at a scheduled meeting of the",
      "page": 93
    },
    {
      "level": "H2",
      "text": "Peripheral and Central Nervous Systems Drugs Advisory Committee",
      "page": 93
    },
    {
      "level": "H1",
      "text": "17. Recommendation",
      "page": 93
    },
    {
      "level": "H2",
      "text": "Deferred, pending discussion of this application at a scheduled meeting of the",
      "page": 93
    },
    {
      "level": "H2",
      "text": "Peripheral and Central Nervous Systems Drugs Advisory Committee",
      "page": 93
    },
    {
      "level": "H2",
      "text": "Ranjit B. Mani, M.D.",
      "page": 93
    },
    {
      "level": "H2",
      "text": "rbm 4/18/06",
      "page": 93
    },
    {
      "level": "H2",
      "text": "cc:",
      "page": 93
    },
    {
      "level": "H2",
      "text": "HFD-120",
      "page": 93
    },
    {
      "level": "H2",
      "text": "NDA 20823 (SE1-016)",
      "page": 93
    }
  ]
}